<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001801.pub2" GROUP_ID="ENT" ID="207499071912083800" MERGED_FROM="" MODIFIED="2010-09-08 19:36:25 +0200" MODIFIED_BY="Jenny Bellorini" REVIEW_NO="0060" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2010-09-08 19:36:25 +0200" MODIFIED_BY="Jenny Bellorini">
<TITLE>Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children</TITLE>
<CONTACT MODIFIED="2010-09-08 19:36:25 +0200" MODIFIED_BY="Jenny Bellorini"><PERSON ID="12011" ROLE="AUTHOR"><PREFIX>Prof.</PREFIX><FIRST_NAME>George</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Browning</LAST_NAME><POSITION>Professor &amp; Honorary Consultant</POSITION><EMAIL_1>ggb@ihr.gla.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>MRC Institute of Hearing Research (Scottish Section)</DEPARTMENT><ORGANISATION>Glasgow Royal Infirmary</ORGANISATION><ADDRESS_1>Queen Elizabeth Building</ADDRESS_1><ADDRESS_2>16 Alexandra Parade</ADDRESS_2><CITY>Glasgow</CITY><ZIP>G31 2ER</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)141 211 4695</PHONE_1><FAX_1>+44 (0)141 552 8411</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-09-08 19:36:25 +0200" MODIFIED_BY="Jenny Bellorini"><PERSON ID="12011" ROLE="AUTHOR"><PREFIX>Prof.</PREFIX><FIRST_NAME>George</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Browning</LAST_NAME><POSITION>Professor &amp; Honorary Consultant</POSITION><EMAIL_1>ggb@ihr.gla.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>MRC Institute of Hearing Research (Scottish Section)</DEPARTMENT><ORGANISATION>Glasgow Royal Infirmary</ORGANISATION><ADDRESS_1>Queen Elizabeth Building</ADDRESS_1><ADDRESS_2>16 Alexandra Parade</ADDRESS_2><CITY>Glasgow</CITY><ZIP>G31 2ER</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)141 211 4695</PHONE_1><FAX_1>+44 (0)141 552 8411</FAX_1></ADDRESS></PERSON><PERSON ID="11975" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maroeska</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Rovers</LAST_NAME><POSITION>Epidemiologist</POSITION><EMAIL_1>m.rovers@umcutrecht.nl</EMAIL_1><URL>http://www.juliuscenter.nl</URL><ADDRESS><DEPARTMENT>Department of Otorhinolaryngology &amp; Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 AB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 253 9005</PHONE_1><FAX_1>+31 253 9028</FAX_1></ADDRESS></PERSON><PERSON ID="11964" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ian</FIRST_NAME><LAST_NAME>Williamson</LAST_NAME><SUFFIX>MB ChB, MRCGP, FRCS, MD</SUFFIX><POSITION>Senior Lecturer in Primary Care</POSITION><EMAIL_1>igw@soton.ac.uk</EMAIL_1><EMAIL_2>I.G.Williamson@soton.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Community Clinical Sciences</DEPARTMENT><ORGANISATION>University of Southampton School of Medicine</ORGANISATION><ADDRESS_1>Aldermoor Health Centre</ADDRESS_1><ADDRESS_2>Aldermoor Close</ADDRESS_2><CITY>Southampton</CITY><ZIP>SO16 5ST</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 23 8024 1061</PHONE_1><PHONE_2>+44 23 8024 1071</PHONE_2><FAX_1>+44 23 8070 1125</FAX_1></ADDRESS></PERSON><PERSON ID="6496" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jørgen</FIRST_NAME><LAST_NAME>Lous</LAST_NAME><POSITION>ENT Group Editor</POSITION><EMAIL_1>jlous@health.sdu.dk</EMAIL_1><ADDRESS><DEPARTMENT>Institut for Sundhedstjenesteforskning</DEPARTMENT><ORGANISATION>Syddansk Universitetscenter</ORGANISATION><ADDRESS_1>Campusvej 55</ADDRESS_1><CITY>Odense M</CITY><ZIP>5230</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 65503031</PHONE_1></ADDRESS></PERSON><PERSON ID="BE67C2AB82E26AA2014A5594476783BD" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Martin</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Burton</LAST_NAME><POSITION>Consultant Otolaryngologist</POSITION><EMAIL_1>mburton2@cochrane-ent.org</EMAIL_1><ADDRESS><DEPARTMENT>Department of Otolaryngology - Head and Neck Surgery</DEPARTMENT><ORGANISATION>Oxford Radcliffe Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Level LG1, West Wing</ADDRESS_1><ADDRESS_2>John Radcliffe Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 231051</PHONE_1><FAX_1>+44 1865 231091</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-03-22 11:32:05 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="22" MONTH="3" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="3" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="3" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2010-07-15 15:10:58 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-07-15 15:10:58 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>Following new searches in March 2010 the review was updated. We included one new study (<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK> - unpublished data) and new data from several long-term follow-up reports of studies already included in the review (<LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK>; <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>).</P>
<P>The authorship of the review also changed in 2010.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-07-06 13:54:48 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-07-06 13:54:48 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-07-30 09:43:20 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>The Institute and Research Unit of General Practice, Århus University</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Århus University Research Foundation</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Institute of Public Health, University of Southern Denmark</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-07-30 09:43:20 +0100" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>The Foundation for Research in General Practice and the Health Care System</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-07-30 09:43:20 +0100" MODIFIED_BY="[Empty name]">
<NAME>UK National Institute for Health Research Cochrane Review Incentive Scheme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-09-08 18:31:40 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-09-08 18:06:07 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-21 12:13:45 +0100" MODIFIED_BY="Jenny Bellorini">Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children</TITLE>
<SUMMARY_BODY MODIFIED="2010-09-08 18:06:07 +0100" MODIFIED_BY="[Empty name]">
<P>Evidence suggests that grommets only offer a short-term hearing improvement in children with simple glue ear (otitis media with effusion or OME) who have no other serious medical problems or disabilities. No effect on speech and language development has been shown.</P>
<P>Glue ear is the build up of thick fluid behind the ear drum. It is a common childhood disorder, affecting one or both ears, and is the major cause of transient hearing problems in children. The insertion of grommets (ventilation or tympanostomy tubes) into the ear drum is a surgical treatment option commonly used to improve hearing in children with bilateral glue ear as unilateral glue ear results in minimal, if any, hearing disability. This review found that in children with bilateral glue ear that had not resolved after a period of 12 weeks and was associated with a documented hearing loss, the beneficial effect of grommets on hearing was present at six months but diminished thereafter. Most grommets come out over this time and by then the condition will have resolved in most children. The review did not find any evidence that grommets help speech and language development but no study has been performed in children with established speech, language, learning or developmental problems. Active observation would appear to be an appropriate management strategy for the majority of children with bilateral glue ear as middle ear fluid will resolve spontaneously in most children. <I>
<BR/>
</I>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-09-08 11:50:04 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]">
<P>Otitis media with effusion (OME; 'glue ear') is common in childhood and surgical treatment with grommets (ventilation tubes) is widespread but controversial.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness of grommet insertion compared with myringotomy or non-surgical treatment in children with OME. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane ENT Disorders Group Trials Register, other electronic databases and additional sources for published and unpublished trials (most recent search: 22 March 2010).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-08-23 08:13:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials evaluating the effect of grommets. Outcomes studied included hearing level, duration of middle ear effusion, language and speech development, cognitive development, behaviour and adverse effects.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-07-30 08:56:13 +0100" MODIFIED_BY="[Empty name]">
<P>Data from studies were extracted by two authors and checked by the other authors.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-09-08 11:48:22 +0100" MODIFIED_BY="[Empty name]">
<P>We included 10 trials (1728 participants). Some trials randomised children (grommets versus no grommets), others ears (grommet one ear only). The severity of OME in children varied between trials. Only one 'by child' study (MRC: TARGET) had particularly stringent audiometric entry criteria. No trial was identified that used long-term grommets.</P>
<P>Grommets were mainly beneficial in the first six months by which time natural resolution lead to improved hearing in the non-surgically treated children also. Only one high quality trial that randomised children (N = 211) reported results at three months; the mean hearing level was 12 dB better (95% CI 10 to 14 dB) in those treated with grommets as compared to the controls. Meta-analyses of three high quality trials (N = 523) showed a benefit of 4 dB (95% CI 2 to 6 dB) at six to nine months. At 12 and 18 months follow up no differences in mean hearing levels were found.</P>
<P>Data from three trials that randomised ears (N = 230 ears) showed similar effects to the trials that randomised children. At four to six months mean hearing level was 10 dB better in the grommet ear (95% CI 5 to 16 dB), and at 7 to 12 months and 18 to 24 months was 6 dB (95% CI 2 to 10 dB) and 5 dB (95% CI 3 to 8 dB) dB better.</P>
<P>No effect was found on language or speech development or for behaviour, cognitive or quality of life outcomes.</P>
<P>Tympanosclerosis was seen in about a third of ears that received grommets. Otorrhoea was common in infants, but in older children (three to seven years) occurred in &lt; 2% of grommet ears over two years of follow up.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-09-08 11:50:04 +0100" MODIFIED_BY="[Empty name]">
<P>In children with OME the effect of grommets on hearing, as measured by standard tests, appears small and diminishes after six to nine months by which time natural resolution also leads to improved hearing in the non-surgically treated children. No effect was found on other child outcomes but data on these were sparse. No study has been performed in children with established speech, language, learning or developmental problems so no conclusions can be made regarding treatment of such children.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-09-08 18:31:40 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-09-08 13:28:54 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane Review first published in <I>The Cochrane Library</I> in Issue 1, 2005.</P>
<SUBSECTION>
<HEADING LEVEL="2">Prevalence and symptoms</HEADING>
<P>Otitis media with effusion (OME) is the chronic accumulation of mucus within the middle ear and sometimes the mastoid air cell system. The prevalence is bimodal with the first and largest peak of 20% at two years of age and a second peak of approximately 16% at around five years of age (<LINK REF="REF-Zielhuis-1990" TYPE="REFERENCE">Zielhuis 1990</LINK>). The first peak relates to episodes of OME that frequently follow acute otitis media and the second peak coincides with an increase in upper respiratory tract infections due to closer association with other children at school. Natural resolution of the OME is the most likely outcome, albeit there may be further episodes. In the majority of children, their OME only causes a mild hearing impairment that is unlikely to be disabling and is of short duration. The clinical dilemma is how to identify children that are likely to have bilateral, persistent OME associated with a degree of hearing loss that is disabling and has the potential to impact on their health and development.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Medical management</HEADING>
<P>A recent meta-analysis (<LINK REF="REF-Griffin-2006" TYPE="REFERENCE">Griffin 2006</LINK>) and a review (<LINK REF="REF-Williamson-2010" TYPE="REFERENCE">Williamson 2010</LINK>) have come to the conclusion that in childhood OME oral antibiotics, mucolytics and antihistamines with oral decongestants are not effective therapies. In addition, a recent trial of topical nasal steroids has shown these not to be effective (<LINK REF="REF-Williamson-2009" TYPE="REFERENCE">Williamson 2009</LINK>). Oral steroids as a treatment for OME remain unproven and adverse effects include growth retardation (<LINK REF="REF-Thomas-2006" TYPE="REFERENCE">Thomas 2006</LINK>). Thus currently there is no proven medical management for OME.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Non-surgical options</HEADING>
<P>The use of bone conduction hearing aids on a head band is increasingly being advocated for children with craniofacial abnormalities associated with persistent ear disease over many years. These may be an option for the management of children with OME. Such aids have the advantage over conventional air-conduction aids in that there are no problems with ear mould fitting and there is no potential for inner ear damage due to excessive amplification if the OME resolves. Such aids appear to be acceptable to parents and children and require evaluation with an appropriate clinical trial.</P>
<P>The only other alternative is auto-inflation with balloons using a commercial nose piece (e.g. Otovent®) (<LINK REF="REF-Perera-2006" TYPE="REFERENCE">Perera 2006</LINK>). The UK National Institute for Health Research Health Technology Assessment programme has invited applications for a clinical trial of these. Almost certainly a fairly high proportion of children with OME will be unable to comply with this treatment as compliance is age-related.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Surgical options</HEADING>
<P>The Cochrane 2005 review of 'Grommets for hearing loss associated with otitis media with effusion in children' (<LINK REF="REF-Lous-2005" TYPE="REFERENCE">Lous 2005</LINK>) identified 13 randomised controlled trials and found that the benefit to hearing appeared to be small. Since then individual patient data from a UK Medical Research Council (MRC)-funded trial (<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>) of children (376 children aged 3.5 to seven years) with persistent bilateral OME and a minimum hearing impairment of 20 dB HL in both ears have been made available to us. This trial randomised children to treatment (rather than ears - see below) and included older children than the two previous studies in the 2005 review. In that review there were also three trials that randomised each ear of children in this age group to different treatments. Such 'by ear' studies, though valuable, cannot be generalised to clinical practice where you treat a child, i.e. it is conventional for both ears to receive the same treatment. Comparison of the 'by child' trials with the 'by ears' trials became an achievable and desirable objective, whilst the combination of the data from both types of trials was not considered to be meaningful.</P>
<P>The availability of these additional trial data allowed modification of the methods of the original 2005 Cochrane Review which included trials (or arms of trials) where children had adenoidectomy in addition to grommets. The adjuvant role of adenoidectomy is now being covered in another review (<LINK REF="REF-van-den-Aardweg-2010" TYPE="REFERENCE">van den Aardweg 2010</LINK>) and this provided us with the opportunity to concentrate on grommets as sole therapy.</P>
<P>The 2005 review had two primary outcomes: difference in hearing levels and presence or absence of fluid in the middle ear cavity or days with fluid. We felt that the presence of fluid should be a secondary outcome as it is the duration of the hearing impairment associated with fluid that increasingly is being recognised as the main symptom requiring management. Audiometric assessment of hearing has the advantage in a surgical trial of being relatively free from observer bias whereas the presence or otherwise of an effusion can be a biased observation. Having a primary outcome that is objective lowers the overall risk of bias and improves the quality of a surgical trial.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-07-29 22:26:59 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness of grommet insertion compared with myringotomy or non-surgical treatment in children with OME.<BR/>
</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-09-08 17:55:42 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-09-08 17:55:42 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-09-07 12:28:01 +0100" MODIFIED_BY="[Empty name]">
<P>Children aged 1 to 12 years with unilateral or bilateral otitis media with effusion. We included children if they had received short courses of analgesics or antibiotics for episodes of acute infection or in the pre-randomisation period. Decongestants could be used freely in any of the groups. Clinical diagnosis was by a combination of otoscopy (including  pneumatic and microscopic), tympanometry and audiometry.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-07-27 15:17:31 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment in the form of grommet insertion in the tympanic membrane could be unilateral (randomisation by ears) with no surgery or myringotomy in the other ear as control, or bilateral (randomisation by children) with no surgery or myringotomy alone in the control group. The difference between the comparison groups was therefore only presence or absence of grommet insertion. The non-grommet treatment group could be (i) no therapy or (ii) conventional incisional myringotomy. In studies where patients in one arm of the trial received adenoidectomy, we excluded the adenoidectomy arm. The role of adenoidectomy in children with otitis media with effusion is evaluated in a separate Cochrane Review (<LINK REF="REF-van-den-Aardweg-2010" TYPE="REFERENCE">van den Aardweg 2010</LINK>).<BR/>
</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-09-08 17:55:42 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-09-08 17:55:42 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome measure was difference in hearing level.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-07-30 08:59:41 +0100" MODIFIED_BY="[Empty name]">
<P>Secondary outcome measures included the following effects (as measured by appropriate tests):</P>
<OL>
<LI>presence or absence of fluid in the middle ear or days with fluid;</LI>
<LI>language and speech development;</LI>
<LI>cognitive development;</LI>
<LI>behaviour;</LI>
<LI>quality of life and health utilities (general and specific, including impact on family and reported hearing difficulties);</LI>
<LI>repeat/revision surgery;</LI>
<LI>adverse effects, including tympanosclerosis, permanent perforation, otorrhoea, hearing loss, pars tensa atrophy and cholesteatoma.</LI>
</OL>
<P>Desirable time points of outcome assessment included one, three, six, nine, 12, 18 and 24 months, and five years.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-09-07 12:28:10 +0100" MODIFIED_BY="[Empty name]">
<P>We conducted systematic searches for randomised controlled trials. There were no language, publication year or publication status restrictions. The date of the last search was 22 March 2010, following previous searches in March 2003, August 2006 and June 2009.</P>
<ELECTRONIC_SEARCHES MODIFIED="2010-09-07 12:28:10 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following databases from their inception for published, unpublished and ongoing trials: the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I> Issue 3, 2010); PubMed; EMBASE; CINAHL; LILACS; KoreaMed; IndMed; PakMediNet; CAB Abstracts; Web of Science; BIOSIS Previews; CNKI; ISRCTN; ClinicalTrials.gov; ICTRP and Google.</P>
<P>We modelled subject strategies for databases on the search strategy designed for CENTRAL. Where appropriate, we combined subject strategies with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in <I>The Cochrane Handbook for Systematic Reviews of Interventions </I>Version 5.0.2, Box 6.4.b. (<LINK REF="REF-Handbook-2009" TYPE="REFERENCE">Handbook 2009</LINK>)). Search strategies for major databases including CENTRAL are provided in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-08-02 15:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>We scanned the reference lists of identified publications for additional trials and contacted trial authors where necessary. In addition, we searched PubMed, TRIPdatabase, NHS Evidence - ENT &amp; Audiology and Google to retrieve existing systematic reviews relevant to this systematic review, so that we could scan their reference lists for additional trials. In previous searches, review authors' own files were scanned for relevant studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-09-07 13:14:13 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-09-07 12:29:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (GGB and MJB) scanned the abstracts of studies derived from the search to identify studies which loosely met the inclusion criteria. The same two authors obtained and reviewed the full texts of these articles and applied the inclusion criteria independently. Any differences in opinion about which studies to include in the review were resolved by discussion between the two authors. As the authors already knew several of the studies eligible for inclusion, we did not consider blinding practicable.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-09-07 12:30:10 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data from the studies using standardised data forms. We extracted data to allow an intention-to-treat analysis. After all the data forms were completed, the first authors of the trials that might be included received a copy for comments if there was any doubt about the data. Where data were missing, we contacted the authors of the study requesting the missing data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-09-07 13:14:13 +0100" MODIFIED_BY="[Empty name]">
<P>GGB and MJB undertook assessment of the risk of bias of the included trials independently with the following taken into consideration, as guided by <I>The Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Handbook-2009" TYPE="REFERENCE">Handbook 2009</LINK>):</P>
<UL>
<LI>sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding;</LI>
<LI>incomplete outcome data;</LI>
<LI>selective outcome reporting; and</LI>
<LI>other sources of bias.</LI>
</UL>
<P>We used the Cochrane &#8216;Risk of bias&#8217; tool in RevMan 5.0 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>), which involves describing each of these domains as reported in the trial and then assigning a judgement about the adequacy of each entry. This involved answering a pre-specified question whereby a judgement of &#8216;Yes&#8217; indicates low risk of bias, &#8216;No&#8217; indicates high risk of bias, and &#8216;Unclear&#8217; indicates unclear or unknown risk of bias. Our assessments are presented in 'Risk of bias' tables (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> (primary studies), <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> (follow-up papers)) and a 'Risk of bias' summary and graph (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-09-07 12:31:07 +0100" MODIFIED_BY="[Empty name]">
<P>We carried out all the analyses on the basis of intention-to-treat.</P>
<P>We used RevMan version 5.0 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) to carry out the meta-analyses for comparable trials and outcomes. Since all outcome measures (i.e. mean hearing loss, time with effusion and language development) were continuous, we calculated mean differences (MD) or standardised mean differences (SMD) and their corresponding 95% confidence intervals (CIs).</P>
<P>We calculated the summary weighted risk differences and 95% CIs (random-effects model) by the Mantel-Haenszel method, which weighs studies by the number of events in the control group.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-09-08 18:24:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-09-08 13:29:26 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-09-07 12:31:53 +0100" MODIFIED_BY="[Empty name]">
<P>The original searches for this review (2003) identified 581 potentially relevant abstracts. Many of the studies were excluded for methodological reasons, e.g. they were not randomised controlled trials. Studies which focused on the use of grommets in adults were also excluded. Other excluded studies considered the effectiveness of adenoidectomy rather than grommets (see '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table).</P>
<P>For the update of this review new searches were carried out in August 2006, June 2009 and March 2010. In total, after removal of duplicates and sifting, these searches retrieved 188 references. After scanning the titles and abstracts the number of potential studies was reduced to 19, which we retrieved in full text. Following assessment of the full texts we discarded a further 12 references. One study is awaiting assessment as it is unclear from the published paper whether it is a randomised study and we are attempting to establish contact with the authors (<LINK REF="STD-Rohail-2006" TYPE="STUDY">Rohail 2006</LINK>). We excluded three studies as they were randomised controlled trials which did not meet one or more inclusion criteria of this review (<LINK REF="STD-Casselbrant-2009" TYPE="STUDY">Casselbrant 2009</LINK>; <LINK REF="STD-Koopman-2004" TYPE="STUDY">Koopman 2004</LINK>; <LINK REF="STD-Shishegar-2007" TYPE="STUDY">Shishegar 2007</LINK>) (see <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK> below). Four new references were included - all were longer-term follow-up reports of studies already included in the previous review (<LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK>; <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>). One study previously listed as &#8216;ongoing&#8217; is now formally included in the review following the release of unpublished data by the principal investigator (<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>). We also searched for systematic reviews so that we could scan their references for further studies. Ten reviews were found, but no additional studies were identified.</P>
<P>The non-surgical treatments identified in these searches included 'watchful waiting/active monitoring' and antibiotics. We found no randomised controlled trial in which hearing aids or other non-surgical treatments in combination with grommets had been evaluated.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-09-08 13:29:26 +0100" MODIFIED_BY="[Empty name]">
<P>The included studies used a range of designs and outcome measures (see also <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table). All trials identified used short-term grommets.</P>
<P>Designs of the included studies:</P>
<P>A. Randomised by ears to right or left (unilateral) grommet:</P>
<UL>
<LI>
<LINK REF="STD-Maw-1979_x002d_86" TYPE="STUDY">Maw 1979-86</LINK>
</LI>
<LI>
<LINK REF="STD-Black-1990" TYPE="STUDY">Black 1990</LINK>
</LI>
<LI>
<LINK REF="STD-Dempster-1993" TYPE="STUDY">Dempster 1993</LINK>
</LI>
</UL>
<P>B. Randomised by children to bilateral grommets or no grommets:</P>
<UL>
<LI>
<LINK REF="STD-Gates-1987" TYPE="STUDY">Gates 1987</LINK>
</LI>
<LI>
<LINK REF="STD-Rach-1991" TYPE="STUDY">Rach 1991</LINK>
</LI>
<LI>
<LINK REF="STD-Mandel-1992" TYPE="STUDY">Mandel 1992</LINK>
</LI>
<LI>
<LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK>
</LI>
<LI>
<LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>
</LI>
<LI>
<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>
</LI>
<LI>
<LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>
</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">A: Studies randomised by ears to unilateral grommet insertion</HEADING>
<P>These three studies were all randomised controlled trials conducted in secondary care in which the participating children had bilateral OME. The two ears were randomised, i.e. all children had a unilateral grommet inserted in one ear and no surgery or myringotomy in the other ear. These studies were designed to elucidate the effect of treatment with a grommet on hearing and the duration of OME. In studies where children were also randomised to have or not have adenoidectomy, the adenoidectomy children are excluded from the analysis. The outcome measure was the difference in hearing between the ears treated with a grommet and the contralateral control ears.</P>
<P>
<LINK REF="STD-Black-1990" TYPE="STUDY">Black 1990</LINK> included 149 children undergoing surgery for bilateral OME on the basis of 'clinical judgement'. The duration of OME was not documented. The mean preoperative hearing level was about 28 dB HL. As well as being randomised to receive adenoidectomy or not, all children were randomised to myringotomy or no myringotomy in the ear without a grommet. The study therefore comprised four different groups: 1) adenoidectomy and myringotomy in one ear, 2) adenoidectomy and no surgery in one ear, 3) no adenoidectomy and myringotomy in one ear, and 4) no adenoidectomy and no surgery in one ear. In this review, data from the adenoidectomy arms are not included. In 51 (34%) of the 149 ears in which a grommet was inserted, no fluid was found at myringotomy. Data regarding the variation (SE or SD) were not published. The outcomes evaluated at seven weeks, six, 12 and 24 months were: hearing (mean hearing loss of the three worst heard frequencies), tympanometry and parental opinion.</P>
<P>
<LINK REF="STD-Dempster-1993" TYPE="STUDY">Dempster 1993</LINK> included 78 children with OME characterised by (a) an air-bone gap of 15 dB or more, (b) hearing levels of 25 dB HL or worse and (c) type B tympanograms in both ears at two examinations with an interval of 12 weeks. The children were randomised to two groups: 1) adenoidectomy and 2) no adenoidectomy. Subsequently, the children in these two groups were randomised to have a grommet in either the right or left ear. The mean preoperative hearing levels were between 31.4 and 33.5 dB HL in the four groups. Fluid was aspirated from all ears that had a grommet inserted. The outcomes evaluated were hearing (mean air conduction and air-bone gap at 500, 1000 and 2000 Hz) at six and 12 months, tympanometry and adverse effects of treatment.</P>
<P>The <LINK REF="STD-Maw-1979_x002d_86" TYPE="STUDY">Maw 1979-86</LINK> study was a trial undertaken by Maw and colleagues which recruited participants between 1979 and 1986. The early results from the first 150 children recruited were reported in Maw 1984 and Maw 1986 (see <LINK REF="STD-Maw-1979_x002d_86" TYPE="STUDY">Maw 1979-86</LINK> for all references). Further participants were enrolled and the whole group followed up for 10 years. Both the short-term and long-term results for the full sample comprising 222 children aged between two and nine years were reported in Maw 1993 and Maw 1994. The children had a persistent hearing difficulty, bilateral effusions on pneumatic otoscopy, symmetrical hearing loss greater than 25 dB HL at one or more frequencies and a non-type A tympanogram at each of three assessments undertaken six weeks apart. The children were randomised to adeno-tonsillectomy or adenoidectomy or neither, and the ears were randomised to grommet insertion or no surgery. The preoperative mean hearing level was 31 to 33 dB HL. The groups randomised to adenoidectomy +/- tonsillectomy are not included in this review. The relevant outcomes evaluated were: hearing (mean of frequencies tested dB and change in mean hearing threshold), otoscopic assessment and tympanometry, at six and 12 months, annually up to seven years and at 10 years (Maw 1994). Not all these data were available at all time points for each ear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Studies randomised by children to bilateral or no grommets insertion</HEADING>
<P>These seven studies were all randomised controlled trials conducted in secondary care in which the participating children had bilateral OME. The participating children were randomised to either bilateral grommets or 'watchful waiting/active monitoring' (i.e. no grommets or late grommets). In one study this was in combination with randomisation to adenoidectomy or no adenoidectomy (<LINK REF="STD-Gates-1987" TYPE="STUDY">Gates 1987</LINK>). Five later studies did not include adenoidectomy (<LINK REF="STD-Mandel-1992" TYPE="STUDY">Mandel 1992</LINK>; <LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK>; <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>; <LINK REF="STD-Rach-1991" TYPE="STUDY">Rach 1991</LINK>; <LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>). A further trial (<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>) had a third adenoidectomy arm and these children were excluded from the analysis. The studies used a variety of outcome measures (hearing, time with hearing loss, time with effusion, language and cognitive development, and quality of life).</P>
<P>The <LINK REF="STD-Gates-1987" TYPE="STUDY">Gates 1987</LINK> study (reported further in Gates 1989 - see <LINK REF="STD-Gates-1987" TYPE="STUDY">Gates 1987</LINK> for reference) included 491 children aged four to eight with persistent effusion for more than 60 days. At surgery between 57% and 68% had bilateral effusion, 21% to 30% had unilateral effusion and 11% to 16% had no effusion at surgery. The children were randomised to four groups: 1) myringotomy only, 2) grommets only, 3) adenoidectomy and myringotomy and 4) adenoidectomy and grommets. Children in the last two groups are not considered in this review. Preoperative mean hearing was between 26 and 31 dB HL in the four groups. The relevant reported outcomes were: time with hearing loss &#8805; 20 dB HL (three frequency pure tone average) in the better and poorer ears, and time with effusion (otoscopy and tympanometry). Complications were reported.</P>
<P>
<LINK REF="STD-Rach-1991" TYPE="STUDY">Rach 1991</LINK> randomised 52 children aged two to four (mean three years three months). The children had bilateral flat type B tympanograms at two examinations three months apart and were randomised to: 1) grommets or 2) 'watchful waiting/active monitoring'. About two-thirds of the children had OME for more than six months at randomisation. The study examined the effect of grommets on language development (differences in comprehension and expressive language) after six months and did not report any audiometric results. Summary results from the same study are also reported in Zielhuis 1989 (see <LINK REF="STD-Rach-1991" TYPE="STUDY">Rach 1991</LINK> for reference). At the age of seven to eight years 37 of the children were re-evaluated with tests of language, reading and spelling (<LINK REF="STD-Schilder-1993" TYPE="STUDY">Schilder 1993</LINK>).</P>
<P>
<LINK REF="STD-Mandel-1992" TYPE="STUDY">Mandel 1992</LINK> included 111 children with unilateral or bilateral OME for at least two months and excluded children with a mean hearing level of more than 24 dB HL. All children were treated with antibiotics for two weeks before inclusion. Only 59% had bilateral OME at randomisation and the mean hearing level in the worst ear was 24 dB, which means that the children were less affected than in most of the other studies. Children were randomised to three groups: 1) grommets, 2) myringotomy and 3) no surgery. Ninety-seven children (87%) were followed up for three years to evaluate treatment failure (persistent OME bilaterally for four months or unilateral for six months). Hearing level was only reported in about one-third of the children. Only results on hearing from the grommet and no surgery group are included in this review. Other outcomes were treatment failure in the first year, episodes of acute otitis media, days with OME in the first year, and episodes of otorrhoea.</P>
<P>
<LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK> included 182 children with bilateral OME, disruptions to speech, language or behaviour, and bilateral hearing loss (25 dB HL or poorer at 4000 Hz only) for at least three months. The children were randomised to: 1) immediate surgery (bilateral ventilation tube insertion and adenoidectomy if needed) and 2) 'watchful waiting/active monitoring' for at least nine months. The mean age at randomisation was three years. Hearing data were only available for about 80% and only at 4000 Hz because of the young age of the children. Individual patient data were made available by Maw and for the meta-analysis (below) four frequency averages were used. Data on 79% of participants were available at nine months. Mean hearing levels in the ears were between 38 and 40 dB. More than 95% had type B tympanograms. During the nine months, 16 in the 'watchful waiting/active monitoring' group underwent surgery and two in the surgery group did not receive early surgery. Outcomes measured were differences between groups in verbal comprehension and expressive language after nine months. The results at 18 months follow up are excluded because a total of 59 children (76%) in the 'watchful waiting/active monitoring' group had grommets inserted. In other papers reporting aspects of the same study, one (Wilks 2000) examined the effect of early treatment with grommets on behavioural problems and a second (Hall 2009) developmental outcomes in the same cohort up to age seven years (see <LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK> for references). The loss to follow up rates were high.</P>
<P>
<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>, the UK MRC-funded TARGET study ('Trial of Alternative Regimens in Glue Ear Treatment'), randomised 376 children aged 3.7 to seven years with documented persistent bilateral otitis media with effusion over a three-month period and a hearing loss of at least 20 dB HL in both ears. Allocation was into three groups: 122 to active observation, 126 to bilateral grommets and 128 to bilateral grommets with adjuvant adenoidectomy. Several outcomes were evaluated at three, six, 12, 18 and 24 months and those relevant to this review were hearing level, repeat/revision surgery and adverse effects as judged by otoscopy.</P>
<P>
<LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK> embedded a randomised controlled trial in a cohort of 30,099 children invited for routine hearing screening at the age of nine months. The 187 participating children had failed three successive hearing screening tests and were suffering from persistent (four to six months) bilateral OME (confirmed by tympanometry and otoscopy). The children were randomised to: 1) insertion of grommets or 2) 'watchful waiting/active monitoring'. Mean visual reinforced audiometry hearing level in the best ear at randomisation was 46 dB HL in the grommets group and 43 dB HL in the 'watchful waiting/active monitoring' group, and mean age at randomisation was 19 months. The outcomes measured included hearing, tests of language and quality of life at six and 12 months. Hearing and quality of life were reported in separate publications (see <LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>, 2001 references: <I>Ear and Hearing</I> and <I>Archives of Disease in Childhood</I>, respectively).</P>
<P>
<LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK> randomised 429 children (aged 0 to 3 years) who had developed OME for 90 days bilaterally or 135 days unilaterally. Allocation was to one of two groups: 1) grommets inserted as soon as possible or 2) delayed surgery (up to nine months later if still needed). Eighteen per cent had bilateral middle ear effusion for 90 days; 16% unilateral for 135 days or intermittent middle ear effusion (19% bilateral; 47% unilateral) for specified proportions of longer periods (e.g. bilateral for 67% of the last 180 days; unilateral for 67% of the last 270 days). The outcomes measured were hearing, developmental testing (cognition, receptive language, expressive language) at the age of three years, reports of parental stress and child behaviour. In April 2003 the group published more details about the outcomes in relation to pre-randomisation illness patterns and hearing levels (Paradise 2003a), and in August 2003 results from the developmental assessment at the age of four years (Paradise 2003b). Further follow up was reported at five years (Johnston 2004), six years (Paradise 2005) and nine to 11 years of age (Paradise 2007) (see <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK> for all references).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-09-07 12:39:50 +0100" MODIFIED_BY="[Empty name]">
<P>Details of all the excluded studies are in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>All the participants in <LINK REF="STD-Casselbrant-2009" TYPE="STUDY">Casselbrant 2009</LINK> received adenoidectomy and for this reason we excluded the study from the review. <LINK REF="STD-Koopman-2004" TYPE="STUDY">Koopman 2004</LINK> compared laser myringotomy with grommets; there was no 'watchful waiting/active monitoring' group. Moreover, the aim of the study was to assess the effectiveness of laser myringotomy and we felt this was not necessarily comparable with conventional myringotomy.</P>
<P>We have excluded three studies that were included in the previous version of this review because all patients also underwent adenoidectomy (<LINK REF="STD-Brown-1978" TYPE="STUDY">Brown 1978</LINK>; <LINK REF="STD-Richards-1971" TYPE="STUDY">Richards 1971</LINK>; <LINK REF="STD-To-1984" TYPE="STUDY">To 1984</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-09-07 13:14:20 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of randomisation in each study is set out in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. The first three items (adequate sequence generation, allocation concealment and blinding) apply to all subsequent papers reporting other aspects of the trial. The last three items (incomplete outcome data addressed, free of selective reporting and free of other bias) are not necessarily those of the first paper but reflect our summary assessment of the set of papers reporting the study in its entirety. <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> presents the results of our assessment of the risks of bias as reported in each individual paper and these issues are dealt with individually in the discussion that follows.</P>
<P>In all the developmental studies the assessors were blinded to allocation group. All five developmental studies and <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK> described the problem of cross-over between groups. All the 'by child' studies reported detailed information on analysis for potential confounders, even when proper randomisation was done: namely <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>, <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK> and <LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>.</P>
<P>A summary of our risk of bias assessments can be found in the 'Risk of bias' graph (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), 'Risk of bias' summary (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) and 'Risk of bias' summary of follow-up papers (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-09-08 18:24:14 +0100" MODIFIED_BY="[Empty name]">
<P>We believe that the results of any hearing improvement in the individual child are more important than improvement in hearing in individual ears. So far in this review we have reported the details of the 'by ear' studies first as historically these were the first that were undertaken. However, in subsequent parts of this review we will examine the effects of hearing 'by child' first</P>
<SUBSECTION>
<HEADING LEVEL="3">Hearing levels by child</HEADING>
<P>Individual patient data (IPD) meta-analysis could be performed on hearing levels using data from three of the seven trials that randomised by child (<LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK>; <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>; <LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>) because in each case individual patient data were made available to us by the trialists. The other four studies (<LINK REF="STD-Gates-1987" TYPE="STUDY">Gates 1987</LINK>; <LINK REF="STD-Mandel-1992" TYPE="STUDY">Mandel 1992</LINK>; <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>; <LINK REF="STD-Rach-1991" TYPE="STUDY">Rach 1991</LINK>) did not provide mean hearing levels in their papers so are not included in the meta-analysis.</P>
<P>The results of meta-analyses at six to nine months (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and 12 months (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) follow up show that grommets were mainly beneficial in the first six months. At six to nine months follow up the mean hearing level in the children treated with grommets (n = 271) was 4.2 dB better (95% CI 2.4 to 6.0 dB) than the mean hearing levels of those in the 'watchful waiting/active monitoring' group (n = 252) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). At 12 months follow up no differences in mean hearing levels were found primarily due to natural resolution (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>We did not combine the 18-month follow-up data since most children in the 'watchful waiting/active monitoring' group in the <LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK> study received grommets between nine and 18 months, and mean hearing at 18 months was only measured in 45% of the randomised children. In <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>, though follow up was around 80% of children, about 60% that still had bilateral OME in the 'watchful waiting/active monitoring' group at 18 months had switched to surgery.</P>
<P>All three studies in this meta-analysis used 'short-term' grommets which progressively become extruded or non-functioning and thus give lesser potential benefit. <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK> reported 79%, 55%, 18%, 8% and 3% functioning on otoscopy and tympanometry at 3, 6, 12, 18 and 24 months (<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>, 2003 reference). However, the proportion of children eligible for revision surgery because of a persistent bilateral hearing average of at least 25 dB HL was 4%, 8%, 16%, 18% and 15% respectively.</P>
<P>
<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK> gave earlier data at three months where the mean hearing levels in the children treated with grommets (n = 109) and the watchful waiting group (n = 106) were 14.4 and 26.3 dB HL; that is a difference of 11.9 dB (95% CI 9.6 to 14.2 dB). At baseline, the mean hearing level in both groups was 33 dB HL. The corresponding levels at six months were 17.5 dB HL in the children with grommets (n = 106) versus 23.1 dB HL in the watchful waiting children (n = 105). At 12 months the hearing levels were 21.0 dB HL in the grommet children (n = 110) versus 20.5 dB HL in the watchful waiting children (n = 100).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hearing levels by ears</HEADING>
<P>Data on mean hearing levels from all studies that randomised by ears, i.e. one ear was treated with a grommet and the other with 'watchful waiting/active monitoring', could be combined in a meta-analysis (<LINK REF="STD-Black-1990" TYPE="STUDY">Black 1990</LINK>; <LINK REF="STD-Dempster-1993" TYPE="STUDY">Dempster 1993</LINK>; <LINK REF="STD-Maw-1979_x002d_86" TYPE="STUDY">Maw 1979-86</LINK>).  </P>
<P>The results of these meta-analyses (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) showed similar effects to the trials that randomised children in the first 12 months but benefit was maintained in the second year in the one trial that reported at that time. At four to six months follow up the mean hearing level in the treated ears (n = 115) was 10.1 dB (95% CI 1.1 to 19.1 dB) better than in the contra-lateral control ears (n = 115) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). At seven to 12 months follow up the mean hearing level in the treated ears (n = 117) was 5.2 dB (95% CI 0.1 to 10.4 dB) better than in the contra-lateral control ears (n = 117) (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). Only one 'by ear' trial (<LINK REF="STD-Black-1990" TYPE="STUDY">Black 1990</LINK>) followed children up for 24 months and found the mean hearing level in the grommet ears (n = 36) was 2.1 dB (95% CI -2.6 to 6.8 dB) better than the contra-lateral ears (n = 36).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Time with effusion</HEADING>
<P>We were able to combine the data on time with effusion from three trials for both the first year (<LINK REF="STD-Mandel-1992" TYPE="STUDY">Mandel 1992</LINK>; <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>; <LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>) and the first two years (<LINK REF="STD-Gates-1987" TYPE="STUDY">Gates 1987</LINK>; <LINK REF="STD-Mandel-1992" TYPE="STUDY">Mandel 1992</LINK>; <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>).</P>
<P>The results of these meta-analyses (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>) showed a small but significant beneficial effect in those treated with grommets. In the first and first two years after randomisation the children treated with grommets spent 32% (95% CI 17% to 48%) and 13% (95% CI 8% to 17%) less time with effusion as compared to those in the 'watchful waiting/active monitoring' group, respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Impact on child health and development</HEADING>
<P>The global impact of OME on the child's life, and on several key aspects of their development, is regarded as clinically highly important and has been investigated in randomised studies that use a variety of different outcomes (for example, proxy parental reported measures, age-specific child tests (e.g. of comprehension), or auditory performance tests (e.g. speech in noise)). Domains considered most relevant include speech and language, cognition and mental development, behaviour, impact on the family, physical health, reported hearing difficulty, and their overall effect on quality of life and functioning.</P>
<P>Four randomised studies that have been followed up as cohorts evaluated both specific and general developmental outcomes. The trials identified were clinically heterogeneous, with a large number of outcomes for which there are concerns. Age-related test reliability and validity also restricted the meta-analyses available, which were only possible for some of the speech and language tests. Time to follow up ranged widely from immediately post-surgery to eight years after in some children (who had received grommets when aged three years) (<LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>, 2007 reference). </P>
<SUBSECTION>
<HEADING LEVEL="4">Language and speech development</HEADING>
<P>We were able to combine the data on language development from three trials that used the same outcome measurement in a meta-analysis (<LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK>; <LINK REF="STD-Rach-1991" TYPE="STUDY">Rach 1991</LINK>; <LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>).</P>
<P>The results of these meta-analyses (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>; <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>) did not show a beneficial effect of grommets regarding comprehensive and expressive language development as compared to 'watchful waiting/active monitoring'. Another trial that used different outcome measures (<LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>) did not find a beneficial effect of early insertion of grommets as compared to 'watchful waiting/active monitoring' at the ages of three, four and nine to 11 years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cognitive development</HEADING>
<P>Two randomised trials, those of <LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK> and <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK> (2007 reference), did not find significant differences between groups on the Griffiths mental scale and McCarthy cognitive index (both general scales).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Behaviour</HEADING>
<P>
<LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK> did not find any differences in the Richman score between early and delayed surgery groups at 18 months (<LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK>, 2000 reference). This measure is a general behavioural measure based on 12 items predictive of behavioural problems. Although emotional problems were noted more often by teachers in children in the delayed group in a later analysis of the same cohort (<LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK>, 2009 reference), this is not a reliable finding because of methodological weaknesses. Specifically, the loss to follow up at age seven years (approximately four years post-baseline) was high, as were the number of measures used, and the study was also underpowered. In the Paradise cohort at 2001 and 2007 a child behaviour checklist was used and was not significantly different between groups at either time point (<LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>, 2001 and 2007 references).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life and health utilities</HEADING>
<P>
<LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK> did not find a significant quality of life improvement using the TAIQOL scale at either six or 12 months post-randomisation between groups (<LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>, 2001 reference (<I>Archives of Disease in Childhood</I>)). The OM8-30 is an otitis media-specific health measure developed from TARGET children but has yet to be fully reported as an outcome from the TARGET study.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">
<I>Repeat/revision surgery</I>
</HEADING>
<P>Three 'by child' studies reported revision surgery rates. <LINK REF="STD-Gates-1987" TYPE="STUDY">Gates 1987</LINK> reported that 28% of children allocated to grommets alone had surgical retreatment in the two-year follow-up period and <LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK> reported 25% repeat/revision surgery in the 18-month follow-up period. The revision surgery figure in <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK> was 35% over a two-year period. Of these, 77% had bilateral hearing thresholds &gt; 20 dB HL and the other 33% other indications. This overall percentage of 35% that had repeat/revision surgery is little different from the 33% that became eligible because their thresholds were <U>&gt;</U> 20 dB HL following their bilateral ventilation tube becoming non-functioning. However, around a third of such eligible children did not have revision surgery.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects of grommets</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Tympanosclerosis</HEADING>
<P>One 'by ear' and one 'by child' study reported the otoscopic presence of tympanosclerosis. <LINK REF="STD-Dempster-1993" TYPE="STUDY">Dempster 1993</LINK> found this present at one year in 38% of ears that had had grommets versus 1% of ears that had no grommets. <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK> at 24 months reported an incidence of 27% of tympanosclerosis in grommet ears versus 0% in those that had not had one.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Perforation and otorrhoea</HEADING>
<P>The majority of ears heal spontaneously following grommet extrusion but in some, particularly if the ear is prone to episodes of acute otitis media, a perforation persists. The only data in included trials are from <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK> where at 24 months two of 634 (&lt; 1%) had a persistent perforation. Otorrhoea only occurred in fewer than 15 of the 634 (2%) ears at any time in the 24-month follow-up period in ears that had grommets. This is in contrast to the <LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK> study in which the participants were much younger infants. In that study the incidence of otorrhoea peaked at six months in 49% (95% CI 39% to 60%) of grommet ears compared with 10% (95% CI 4% to 16%) of non-grommet ears (<LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>, 2005 reference). In the Gates study of children aged four to eight years, where there was a high incidence of acute otitis media in the non-grommet ear of 11%, the grommet ear had an incidence of around 27% (<LINK REF="STD-Gates-1987" TYPE="STUDY">Gates 1987</LINK>, 1989 reference).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long-term hearing loss</HEADING>
<P>The early treatment group in <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK> had an increased risk difference of 28% (95% CI 20% to 36%) more tympanic membrane abnormalities than the late treatment group. They reported in the later follow-up paper that ears with tympanic membrane abnormalities had between -0.3 and 3.0 dB lower hearing levels compared with tympanic membranes without abnormalities (<LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>, 2004 reference).<B> </B>
</P>
<P>Two to five years after treatment with grommets no significant hearing difference was found. In some of the studies a new grommet was inserted if fluid recurred after extrusion of the original tube. This could have biased the results. Information on other complications was inconclusive because of few studies.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-09-08 18:28:30 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2010-09-08 18:28:30 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Hearing</HEADING>
<P>The children in our IPD meta-analysis of the trials randomising children and not ears were towards the more severe end of a spectrum of children with OME; they had persistent, bilateral effusions with well-documented hearing levels. In these children, treatment with grommets has a small beneficial effect on both the mean hearing levels and the time with effusion. The magnitude of the hearing benefit is greatest at three months, being in the region of 12 dB, but this drops at six to nine months to only 4 dB. This later figure is within the test/retest error for audiometry in an individual child.</P>
<P>This hearing benefit is very similar to the benefit seen in the randomisation by ear studies. In these, at four to six months the benefit was 10 dB and at seven to 12 months 5 dB. Because of this any cross-over to surgery from 'watchful waiting/active monitoring' in the 'by child' studies has had an effect that is marginal at most.</P>
<P>The reduction in benefit over time is understandable because of natural resolution of the OME in the non-operated children. It is a coincidence that the time that this occurs is when an increasing proportion of the grommets becoming non-functioning. What is less obvious is why, prior to six months, the hearing improvement is not greater in children whose mean hearing level is in the region of 30 dB HL. One factor of interest, previously reported from TARGET data (<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>, 2003 reference), may be deduced from observing that at three months, when only ears with functioning grommets were analysed, the residual air-conduction thresholds were 11.9 dB HL (95% CI 11.2 to 12.4 dB HL) and there was an air-bone gap of 13.5 dB (95% CI 12.5 to 14.5 dB). This persistent conductive defect, seen even when grommets are in situ and functioning, was postulated to be due to mucosal oedema around the ossicular chain that had not been resolved by ventilating the middle ear with the grommet. It is also recognised that even after resolution of otoscopic and tympanometric fluid there is still a small conductive hearing loss which persists for many years (<LINK REF="REF-de-Beer-2004" TYPE="REFERENCE">de Beer 2004</LINK>; <LINK REF="REF-Caye_x002d_Thomasen-2008" TYPE="REFERENCE">Caye-Thomasen 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Time with effusion</HEADING>
<P>This outcome, in comparison to hearing levels, has several weaknesses. It is calculated from whether fluid was present or not at postoperative time intervals that vary by study. As otoscopy is part of the assessment of whether fluid is present, blindness as to the presence of a grommet or its sequelae is not possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Impact on child health and development</HEADING>
<P>No effects were found regarding the impact of grommets on the potential sequelae which have been studied and reported in this review. These include speech and language development at periods up to 11 years, cognitive development and behaviour. The lack of quality of life improvement in the Rovers study may be partly explained by the fact that most children did not have any quality of life problems at baseline. Furthermore, they used a generic quality of life measure which has not been validated for otitis media, whereas other specific otitis media quality of life measurements are now available.</P>
<P>This lack of effect on any of the developmental scales, however, raises a question as to whether the magnitude of improvement in hearing reported above is likely to make any material difference to these outcomes. The answer to this has not been evaluated but an effect is unlikely.</P>
<P>This raises the further question as to whether in the long-term there are any detrimental effects in the vast majority of children with otitis media, even at the more severe end of a spectrum of persistence and hearing loss. The hypothesis here being that the hearing-deprived period is rapidly compensated for by the flexibility of development in children. No study that randomised children to grommets versus 'watchful waiting/active monitoring' demonstrated a significant effect on any developmental outcome in either group compared with 'normal' non-otitis media with effusion controls.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Revision surgery</HEADING>
<P>All the trials reported in this review used 'short-term' grommets.</P>
<P>Papers that report revision/repeat surgery rates (<LINK REF="STD-Gates-1987" TYPE="STUDY">Gates 1987</LINK>; <LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK>; <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>) suggest that around 30% of children that have had grommets have re-operations. Revision surgery is done for many reasons apart from persistence of a hearing impairment. Good quality data on the proportion of children that are eligible because of persistence of a hearing impairment are not available. The data from the adenoidectomy arm in these trials suggest that the repeat/revision surgery rate can be reduced to around 10% if adjuvant adenoidectomy is performed at the same time as grommet insertion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects of grommets</HEADING>
<P>This review confirms many previous reports from other studies that grommets are associated with tympanosclerosis in around a third of ears (<LINK REF="REF-Kay-2001" TYPE="REFERENCE">Kay 2001</LINK>).</P>
<P>Children with established otitis media with effusion treated with grommets in the age group three to seven years are not likely to have otorrhoea postoperatively or develop permanent perforations. This is in contrast to younger children and different indications, such as recurrent acute otitis media, where both have a higher incidence and necessitate intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Long-term hearing loss</HEADING>
<P>Two studies have now followed up children with OME for more than a decade. <LINK REF="REF-de-Beer-2004" TYPE="REFERENCE">de Beer 2004</LINK>, a cohort study, found a persistent small (~2 dB HL) conductive hearing impairment in non-surgically managed OME children compared with non-OME children (~0 dB HL). Children that had had grommets had poorer hearing (5 to 10 dB HL) than those that had not had grommets. <LINK REF="REF-Caye_x002d_Thomasen-2008" TYPE="REFERENCE">Caye-Thomasen 2008</LINK> followed up OME children where the right ear had a grommet and the left ear a myringotomy and found that there was a persistent hearing impairment (~8 dB HL) but no difference between the right and left ears.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-09-07 12:48:16 +0100" MODIFIED_BY="[Empty name]">
<P>The included studies in large part address the question we posed at the outset of the review. Some of the participants in the trials included in the earlier version of this review were characterised by potentially mild disease. That is, the entry criteria for the individual studies did not require participants to have had marked disease (as determined by hearing levels) that persisted over a long period (two evaluations, a fixed interval apart prior to study entry).</P>
<P>In contrast the current review <I>does</I> include studies enrolling children with persistent OME and a documented hearing impairment over a wide range. However, we note that the more severely affected children (<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>) do not seem to have significantly different results compared to others (<LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK>; <LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). </P>
<P>Subgroups that might benefit more from treatment with grommets include those with speech or language delays, behaviour and learning problems, Down&#8217;s syndrome, or children with cleft palate. These could not be studied in this review as these subgroups were excluded in all included individual trials.</P>
<P>No evidence was available concerning some outcomes that we felt to be important and were included in our protocol.</P>
<P>How do the results of this review fit into the context of current practice? There is wide variation both within and between countries in the rates at which grommets are inserted. In some countries, relatively stringent criteria are recommended by national guidelines. In the UK, for example, NICE guidance (<LINK REF="REF-NICE-2008" TYPE="REFERENCE">NICE 2008</LINK>) suggests grommets be considered in children (without special risk factors) with a type of persistent bilateral disease and hearing loss that is slightly more severe than in children in the TARGET trial. Our review suggests that even in such children, the measured hearing improvement is very modest. The NICE guidelines provide a caveat that the audiological criteria may be less where the impact of the hearing loss on a child's developmental, social or educational status is judged to be significant. The studies examined in this review did not necessarily include children with marked developmental, social or educational problems so the results of the review cannot be applied to these children, nor indeed to those specifically excluded from the individual studies - children with Down's syndrome or cleft lip and palate, for example.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-08-25 15:35:35 +0100" MODIFIED_BY="[Empty name]">
<P>The three 'by child' studies providing the primary hearing outcomes in this review had no bias likely to impact upon the hearing outcomes for the meta-analysis.</P>
<P>The three 'by ear' studies reporting hearing levels were also of high quality in this respect, with non-consequential risks of bias.</P>
<P>The three 'by child' studies reporting language and speech development were all of high quality and assessed as at minimal risk of bias.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>To capture all trials relevant to this review, both published and unpublished, we used an extensive search strategy which included more than 14 databases and was subject to no language or publication restrictions. It is possible that studies may have been missed, but unlikely. </P>
<P>Study selection and quality assessment were both undertaken by two authors independently and we have used the Cochrane Collaboration 'Risk of bias' method to ensure transparent assessment and reporting of study quality. </P>
<P>We have been successful in our attempt to obtain and include unpublished data. This review now includes considerable data from the <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK> trial which had not previously been in the public domain.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-09-07 12:48:27 +0100" MODIFIED_BY="[Empty name]">
<P>Several other Cochrane Reviews on treatments for otitis media have been published. A review on the effect of adenoidectomy (<LINK REF="REF-van-den-Aardweg-2010" TYPE="REFERENCE">van den Aardweg 2010</LINK>) showed that adenoidectomy in combination with a unilateral grommet has a small beneficial effect on the resolution of OME and hearing compared to a unilateral grommet only. The results of studies of adenoidectomy with or without myringotomy versus non-surgical treatment or myringotomy only, and those of adenoidectomy in combination with bilateral grommets versus bilateral grommets only, also showed a small beneficial effect of adenoidectomy on the resolution of the effusion. However, since the benefit of all surgery to hearing is small, the authors conclude that the risks of operating should be weighed against the potential benefits, which is in agreement with our findings and conclusion.</P>
<P>Our results are also in agreement with the results of a meta-analysis of individual patient data (<LINK REF="REF-Rovers-2005" TYPE="REFERENCE">Rovers 2005</LINK>), which was performed to identify subgroups of children with OME that might benefit more than others from treatment with grommets. Significant interactions (beneficial effects) were found in young children that grow up in an environment with a high infection load (e.g. children attending day-care) and in older children with a hearing level of 25 dB or greater in both ears for at least 12 weeks. No final conclusion could be drawn on other subgroups that might benefit more, such as children with speech and language delays, behaviour and learning problems, Down's syndrome and children with cleft palate, since these children were not included in the individual studies.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-09-08 18:31:40 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-09-08 18:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>This 2010 update of the review has clarified several issues regarding grommets that were raised in the 2005 review. Adenoidectomy in conjunction with grommets is considered in another Cochrane Review (<LINK REF="REF-van-den-Aardweg-2010" TYPE="REFERENCE">van den Aardweg 2010</LINK>).</P>
<P>All included trials used short-term grommets in children with documented bilateral OME persistent over at least 12 weeks, with age-related thresholds at the more severe end of the spectrum. Older children aged three to seven years with hearing levels of at least 40 dB HL in both ears remain unreported.</P>
<P>It would be helpful if children more likely to benefit from grommets could be identified. The <LINK REF="REF-Rovers-2005" TYPE="REFERENCE">Rovers 2005</LINK> individual patient meta-analysis of 'by ear' studies, mentioned above, concluded that grommets might be used in older children with a hearing level of 25 dB HL or greater in both ears persisting for at least 12 weeks.<B> </B>This review has replicated that finding.</P>
<P>We also replicated the <LINK REF="REF-Rovers-2005" TYPE="REFERENCE">Rovers 2005</LINK> finding that<B> </B>the same audiometric criteria cannot be confirmed as a 'cut-off' point to predict benefit based on the 'by child' studies we report here. We have calculated that grommets give a 2 to 6 dB benefit to children at six to nine months. At this time a high proportion of the short-term grommets are non-functioning but the OME has sufficiently resolved not to merit repeat/revision surgery.</P>
<P>The question here is whether this magnitude of hearing improvement merits a surgical operation. This is a matter of judgement as to what benefit would accrue to an individual child from a mean improvement of 10 to 14 dB at three months and 2 to 6 dB at six to nine months, given the 'starting point' (specific hearing levels) in that child. In making the judgement it has to be remembered that the degree of hearing impairment is associated with greater likelihood of persistence. Data from the TARGET trial show that children with the poorest hearing levels at the outset had the greatest chance of persistence of middle ear fluid and hearing loss (<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>, Browning 2001b reference).</P>
<P>The relatively short-term benefit to hearing of short-term grommets might suggest that longer-term grommets would be more appropriate. This is not the case as the main reason for the small benefit at six to nine months is primarily because of resolution of the OME in the non-surgical children. Correspondingly, short-term grommets are appropriate for the majority of children to give hearing benefit for six months, the time by which the majority of children will have resolved spontaneously.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-09-08 18:31:40 +0100" MODIFIED_BY="[Empty name]">
<P>Despite the efforts of many researchers and patients over more than 25 years there is still uncertainty around the best management strategy for children with OME. Current work to increase our understanding of the basic science underlying this process (including genetics, aetiology, microbiology and immunology) is to be welcomed, as are endeavours to develop novel therapeutic strategies using new technologies.</P>
<P>Clinical research has thus far focused primarily on the commonest interventions (medical treatments and surgery in the form of grommets, with or without adenoidectomy) and on standard patients with mild or moderate disease. This leaves a number of important questions. </P>
<P>The studies included in this review exclude children with other disorders - cleft lip and palate or Down's syndrome, for example - or children with more severe and persistent hearing loss (40 dB HL+). To undertake randomised controlled trials in these groups may be difficult because of a perceived absence of equipoise and the obvious difficulties and expense of such a study design.</P>
<P>Future studies may consider the appropriateness of measuring hearing using pure tone thresholds in quiet. A 'speech in noise' test might be a more appropriate method of assessing eligibility and outcomes as it may more accurately reflect the child's disability. Whilst this is an objective measure that merits serious consideration we are uncertain whether or not the modest benefit on pure tone thresholds found in this review would be associated with significant improvements in the results of speech in noise tests. </P>
<P>Future research might also look at the optimal period of 'watchful waiting/active monitoring'. What would be the effect of extending the currently accepted period from three to six months before considering surgery? This policy is as justified as the current three months of 'watchful waiting/active monitoring' during which time around 50% of children with bilateral OME and a hearing impairment will resolve. If a second three-month active observation period were to be recommended during this time a further ~50% would resolve spontaneously (<LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>, Browning 2001b reference). To make such a policy acceptable to parents the waiting period has to be an active period and research could usefully evaluate the best 'active monitoring' strategy.</P>
<P>Are there any alternatives to grommets other than 'watchful waiting/active monitoring' that have not been evaluated? There are two that need serious consideration. In the UK hearing aids are sometimes used for children with persistent conductive hearing losses due to OME. They appear to be accepted by the children that use them with a remarkable degree of equanimity, are free of the risks associated with surgery and have the potential for raising hearing levels more than grommets because the residual air-bone gap associated with grommets can be closed. Risks include over-amplification after resolution of OME and battery ingestion. Their provision and maintenance by paediatric hearing healthcare professionals ensures that the children also receive a high degree of active monitoring. Any trial evaluating their use would need to understand and be aware of this when selecting the appropriate control group. The other management strategy that requires evaluation is the role of auto-inflation with mechanical devices such as the Otovent®. Previous trials have been equivocal and were not reported on an intention-to-treat basis. Children that could not auto-inflate were excluded from the analysis (<LINK REF="REF-Perera-2006" TYPE="REFERENCE">Perera 2006</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-09-07 12:51:11 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a review original conceived and authored by one of us - Professor Jørgen Lous - and co-authored by five others. We acknowledge the debt we owe to two authors who did not participate in the update (Jens Felding and Therese Ovesen), as well as the significant role Jørgen Lous played in the original review. We thank the Foundation for Research in General Practice and the Danish health system for financial support and are also grateful for support from the Institute and Research Unit of General Practice, Åarhus University, The Research Fund of Åarhus University, the Institute of Public Health and the University of Southern Denmark, all for the original review.</P>
<P>We acknowledge important discussions in Melbourne with Melissa Wake during the early stages of this review.</P>
<P>We are grateful to the lead investigators of the following trials for making data available for the meta-analysis performed for this review: <LINK REF="STD-Black-1990" TYPE="STUDY">Black 1990</LINK>; <LINK REF="STD-Dempster-1993" TYPE="STUDY">Dempster 1993</LINK>; <LINK REF="STD-Maw-1979_x002d_86" TYPE="STUDY">Maw 1979-86</LINK>; <LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK>; <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK>; <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>; <LINK REF="STD-Rach-1991" TYPE="STUDY">Rach 1991</LINK>; <LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>.</P>
<P>The 2010 update of this review was funded by the UK National Institute for Health Research Cochrane Review Incentive Scheme.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-09-07 12:52:23 +0100" MODIFIED_BY="[Empty name]">
<P>GEORGE G BROWNING was the lead clinician but not the principal investigator for the <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK> study and has been involved in the data analysis and writing up of all the currently cited MRC Multi-centre Otitis Media Study Group papers.</P>
<P>MAROESKA ROVERS was the lead investigator and author for the papers cited under <LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK>. She was also involved as an advising epidemiologist in the <LINK REF="STD-MRC_x003a_-TARGET-2001" TYPE="STUDY">MRC: TARGET 2001</LINK> study and is therefore co-author on most MRC Multi-centre Otitis Media Study Group papers. Furthermore, she has participated in workshops and educational activities on otitis media for GlaxoSmithKline.</P>
<P>JØRGEN LOUS in 2008 received funds for research for otitis media related subjects from Oticon Fonden (Oticon foundation) the owner of Interacoustic A/S Assens, Denmark. Interacoustic make tympanometers, audiometers and other acoustic equipment.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-09-08 18:05:05 +0100" MODIFIED_BY="[Empty name]">
<P>GEORGE G BROWNING: Invited to lead the data evaluation and writing team for this updated review. Drafting of abstract, plain language summary, background. Selection of studies. Appraisal of trial risk of bias. Revision surgery and adverse events outcomes. Writing final review.</P>
<P>MAROESKA ROVERS: Comments on the protocol, literature search and the draft review. Data extraction and analysis. Hearing outcomes. Writing final review.</P>
<P>IAN WILLIAMSON: Comments on the protocol, literature search and the draft review. Data extraction. Developmental outcomes. Writing final review.</P>
<P>JØRGEN LOUS: Lead author of original review, review of draft update.</P>
<P>MARTIN J BURTON: Selection of studies. Appraisal of trial risk of bias. Writing final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-09-03 11:17:29 +0100" MODIFIED_BY="[Empty name]">
<P>The following changes were made at the update of the review in 2010:</P>
<SUBSECTION>
<HEADING LEVEL="2">Objectives</HEADING>
<UL>
<LI>We have added assessment of adverse effects as an objective of the review.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Types of interventions</HEADING>
<UL>
<LI>We have excluded arms/trials where children also had adenoidectomy, as this is now covered in a separate review (<LINK REF="REF-van-den-Aardweg-2010" TYPE="REFERENCE">van den Aardweg 2010</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Types of outcome measures</HEADING>
<UL>
<LI>'Presence or absence of fluid in the middle ear cavity or days with fluid' has been changed from a primary to a secondary outcome measure.</LI>
<LI>We have added a new outcome measure: 'Repeat/revision surgery'.</LI>
<LI>Desirable time points for outcome assessment have been changed to one, three, six, nine, 12, 18 and 24 months, and five years.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Quality/risk of bias assessment</HEADING>
<UL>
<LI>We have adopted the Cochrane Collaboration 'Risk of bias' tool for assessment of study quality.</LI>
</UL>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-09-08 18:02:40 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-09-08 18:02:40 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-09-08 18:02:40 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Black-1990" MODIFIED="2010-08-02 11:38:40 +0100" MODIFIED_BY="[Empty name]" NAME="Black 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-08-02 11:38:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Black N</AU>
<SO>Personal correspondence (e-mail) regarding study design</SO>
<YR>July 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-02 11:38:40 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Unilateral tube study.&lt;/p&gt;" NOTES_MODIFIED="2010-08-02 11:38:40 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Black NA, Sanderson CFB, Freeland AP, Vessey MP</AU>
<TI>A randomised controlled trial of surgery for glue ear</TI>
<SO>BMJ</SO>
<YR>1990</YR>
<VL>300</VL>
<NO>6739</NO>
<PG>1551-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dempster-1993" MODIFIED="2010-08-02 16:06:21 +0100" MODIFIED_BY="[Empty name]" NAME="Dempster 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-08-02 16:06:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dempster JH, Browning GG, Gatehouse SG</AU>
<TI>A randomized study of the surgical management of children with persistent otitis media with effusion associated with a hearing impairment</TI>
<SO>Journal of Laryngology and Otology</SO>
<YR>1993</YR>
<VL>107</VL>
<NO>4</NO>
<PG>284-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gates-1987" MODIFIED="2010-08-02 16:06:32 +0100" MODIFIED_BY="[Empty name]" NAME="Gates 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gates GA, Avery CA, Cooper JC Jr, Prihoda TJ</AU>
<TI>Chronic secretory otitis media: effects of surgical management</TI>
<SO>Annals of Otology, Rhinology &amp; Laryngology. Supplement</SO>
<YR>1989</YR>
<VL>138</VL>
<PG>2-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-02 16:06:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gates GA, Avery CA, Prihoda TJ, Cooper JC</AU>
<TI>Effectiveness of adenoidectomy and tympanostomy tubes in the treatment of chronic otitis media with effusion</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>317</VL>
<NO>23</NO>
<PG>1444-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandel-1992" MODIFIED="2010-08-02 16:06:43 +0100" MODIFIED_BY="[Empty name]" NAME="Mandel 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-08-02 16:06:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandel EM, Rockette HE, Bluestone CD, Paradise JL, Nozza RJ</AU>
<TI>Efficacy of myringotomy with and without tympanostomy tubes for chronic otitis media with effusion</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1992</YR>
<VL>11</VL>
<NO>4</NO>
<PG>270-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maw-1979_x002d_86" MODIFIED="2010-08-02 16:06:54 +0100" MODIFIED_BY="[Empty name]" NAME="Maw 1979-86" YEAR="1986">
<REFERENCE MODIFIED="2010-07-29 22:22:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maw AR, Bawden R</AU>
<TI>The long term outcome of secretory otitis media in children and the effects of surgical treatment: a ten year study</TI>
<SO>Acta Oto-Rhino-Laryngologica Belgica</SO>
<YR>1994</YR>
<VL>48</VL>
<NO>4</NO>
<PG>317-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-02 16:06:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maw AR, Herod F</AU>
<TI>Otoscopic, impedance, and audiometric findings in glue ear treated by adenoidectomy and tonsillectomy</TI>
<SO>Lancet</SO>
<YR>1986</YR>
<VL>1</VL>
<NO>8495</NO>
<PG>1399-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-02 11:38:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Maw AR</AU>
<SO>Personal correspondence (e-mail) regarding study design</SO>
<YR>July 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-29 22:23:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maw R, Bawden R</AU>
<TI>Spontaneous resolution of severe chronic glue ear in children and the effect of adenoidectomy, tonsillectomy, and insertion of ventilation tubes (grommets)</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<NO>6880</NO>
<PG>756-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slack RWT, Maw AR, Capper JWR, Kelly S</AU>
<TI>Prospective study of tympanosclerosis developing after grommet insertion</TI>
<SO>Journal of Laryngology and Otology</SO>
<YR>1984</YR>
<VL>98</VL>
<NO>8</NO>
<PG>771-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maw-1999" MODIFIED="2010-08-02 11:39:38 +0100" MODIFIED_BY="[Empty name]" NAME="Maw 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall AJ, Maw AR, Steer CD</AU>
<TI>Developmental outcomes in early compared with delayed surgery for glue ear up to age 7 years: a randomised controlled trial</TI>
<SO>Clinical Otolaryngology</SO>
<YR>2009</YR>
<VL>34</VL>
<PG>12-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-02 11:39:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Maw AR</AU>
<SO>Personal communication (e-mail) regarding study design</SO>
<YR>July 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-07 10:43:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maw R, Wilks J, Harvey I, Peters TJ, Golding J</AU>
<TI>Early surgery compared with watchful waiting for glue ear and effect on language development in preschool children: a randomised trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9157</NO>
<PG>960-3. Erratum in: Lancet 1999;354(9187):1392</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilks J, Maw R, Peters TJ, Harvey I, Golding J</AU>
<TI>Randomised controlled trial of early surgery versus watchful waiting for glue ear: the effect on behavioural problems in pre-school children</TI>
<SO>Clinical Otolaryngology and Allied Sciences</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>3</NO>
<PG>209-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-MRC_x003a_-TARGET-2001" MODIFIED="2010-09-08 18:02:40 +0100" MODIFIED_BY="[Empty name]" NAME="MRC: TARGET 2001" YEAR="1996">
<REFERENCE MODIFIED="2010-09-08 18:02:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Browning GG on behalf of the MRC Multi-centre Otitis Media with Effusion Study Group, Glasgow, UK</AU>
<TI>(NSOCS Abstracts) Two-year outcome of ventilation tubes in a randomized controlled trial of persistent childhood otitis media with effusion</TI>
<SO>Clinical Otolaryngology</SO>
<YR>2001</YR>
<VL>26</VL>
<PG>342-3</PG>
<IDENTIFIERS MODIFIED="2010-09-08 18:02:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-08 18:02:20 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Browning 2001a"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-08 18:02:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Browning GG</AU>
<TI>Watchful waiting in childhood otitis media with effusion (Editorial)</TI>
<SO>Clinical Otolaryngology</SO>
<YR>2001</YR>
<VL>26</VL>
<PG>263-4</PG>
<IDENTIFIERS MODIFIED="2010-09-08 18:02:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-08 18:02:40 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Browning 2001b"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-03 13:58:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MRC Multi-centre Otitis Media Study Group</AU>
<TI>Risk factors for persistence of bilateral otitis media with effusion</TI>
<SO>Clinical Otolaryngology</SO>
<YR>2001</YR>
<VL>26</VL>
<NO>2</NO>
<PG>147-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MRC Multi-centre Otitis Media Study Group</AU>
<TI>The role of ventilation tube status in the hearing levels in children managed for bilateral persistent otitis media with effusion</TI>
<SO>Clinical Otolaryngology</SO>
<YR>2003</YR>
<VL>28</VL>
<PG>146-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-07 13:06:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>MRC Multicentre Otitis Media Study Group. In preparation for submission to Clinical Otolaryngology 2010</AU>
<TI>A randomised controlled trial in otitis media with effusion [TARGET]. Effect of treatments with ventilation tubes and adenoidectomy on measure and reported hearing through 2 years</TI>
<SO>Clinical Otolaryngology</SO>
<YR>(In preparation for submission 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-23 12:20:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MRC Multicentre Otitis Media Study Group</AU>
<TI>Surgery for persistent otitis media with effusion: generalizability of results from the UK trial (TARGET). Trial of Alternative Regimens in Glue Ear Treatment</TI>
<SO>Clinical Otolaryngology and Allied Sciences</SO>
<YR>2001</YR>
<VL>26</VL>
<NO>5</NO>
<PG>417-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Professor Mark Haggard</TI>
<SO>Personal communication October 2009 to August 2010</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>TARGET study: the trial of alternative regimens in glue ear treatment</TI>
<SO>National Research Register</SO>
<IDENTIFIERS MODIFIED="2010-07-07 10:02:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-07-07 10:02:57 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="N0264059127"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Trial of alternative regimens in glue ear treatment - effectiveness of surgery for otitis media with effusion in 3.5-7 year olds using multiple developmental and economic measures combined with classical clinical measures</TI>
<SO>ISRCTN Register (http://www.controlled-trials.com/ISRCTN35793977)</SO>
<IDENTIFIERS MODIFIED="2010-07-07 10:09:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-07-07 10:09:08 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISRCTN35793977"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-07-07 10:03:02 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paradise-2001" MODIFIED="2010-09-07 13:06:23 +0100" MODIFIED_BY="[Empty name]" NAME="Paradise 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnston LC, Feldman HM, Paradise JL, Bernard BS, Colborn DK, Casselbrant ML, et al</AU>
<TI>Tympanic membrane abnormalities and hearing levels at the ages of 5 and 6 years in relation to persistent otitis media and tympanostomy tube insertion in the first 3 years of life: a prospective study incorporating a randomized clinical trial</TI>
<SO>Pediatrics</SO>
<YR>2004</YR>
<VL>114</VL>
<NO>1</NO>
<PG>e58-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Paradise J, Dollaghan C, Campbell T, Feldman H, et al</AU>
<TI>Early vs delayed tube placement for persistent middle-ear effusion in the first three years of life: effects on cognition, language, speech and behavior at ages 4 and 6 years</TI>
<SO>8th International Symposium on Recent Advances in Otitis Media</SO>
<YR>2003</YR>
<PG>219. Abstract No. B57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Paradise J</AU>
<TI>Middle ear disease before age 3, treatment with ear tubes, and literacy and attentional abilities at ages 9 to 11</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00365092</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2010-07-07 10:19:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-07-07 10:19:01 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT00365092"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paradise JL, Campbell TF, Dollaghan CA, Feldman HM, Bernard BS, Colborn DK, et al</AU>
<TI>Developmental outcomes after early or delayed insertion of tympanostomy tubes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>6</NO>
<PG>576-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paradise JL, Dollaghan CA, Campbell TF, Feldman HM, Bernard BS, Colborn DK, et al</AU>
<TI>Otitis media and tympanostomy tube insertion during the first three years of life: developmental outcomes at the age of four years</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>112</VL>
<NO>2</NO>
<PG>265-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paradise JL, Feldman HM, Campbell TF, Dollaghan CA, Colborn DK, Bernard BS, et al</AU>
<TI>Early versus delayed insertion of tympanostomy tubes for persistent otitis media: developmental outcomes at the age of three years in relation to prerandomization illness patterns and hearing levels</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>4</NO>
<PG>309-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-02 16:07:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Paradise JL, Feldman HM, Campbell TF, Dollaghan CA, Colborn DK, Bernard BS, et al</AU>
<TI>Effect of early or delayed insertion of tympanostomy tubes for persistent otitis media on developmental outcomes at the age of three years</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>16</NO>
<PG>1179-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-07 13:06:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paradise JL, Feldman HM, Campbell TF, Dollaghan CA, Rockette HE, Pitcairn DL, et al</AU>
<TI>Tympanostomy tubes and developmental outcomes at 9-11 years of age</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>356</VL>
<PG>248-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rach-1991" MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" NAME="Rach 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rach GH, Zielhuis GA, van Baarle PW, van den Broek P</AU>
<TI>The effect of treatment with ventilating tubes on language development in preschool children with otitis media with effusion</TI>
<SO>Clinical Otolaryngology and Allied Sciences</SO>
<YR>1991</YR>
<VL>16</VL>
<NO>2</NO>
<PG>128-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zielhuis GA, Rach GH, van den Broek P</AU>
<TI>Screening for otitis media with effusion in preschool children</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>8633</NO>
<PG>311-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rovers-2000" MODIFIED="2010-08-02 16:07:35 +0100" MODIFIED_BY="[Empty name]" NAME="Rovers 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-08-02 15:32:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ingels K, Rovers MM, Van der wild GJ, Zielhuis GA</AU>
<TI>Ventilation tubes in infants increase the risk of otorrhoea and the usage of antibiotics</TI>
<SO>B-ENT</SO>
<YR>2005</YR>
<VL>1</VL>
<NO>4</NO>
<PG>173-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rovers M, Krabbe P, Straatman H, Ingels K, van der Wilt G, Zielhuis G</AU>
<TI>Randomised controlled trial of the effect of ventilation tubes (grommets) on quality of life at age 1-2 years</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2001</YR>
<VL>84</VL>
<NO>1</NO>
<PG>45-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rovers MM, Straatman H, Ingels K, van der Wilt GJ, van den Broek P, Zielhuis GA</AU>
<TI>The effect of short-term ventilation tubes versus watchful waiting on hearing in young children with persistent otitis media with effusion: a randomized trial</TI>
<SO>Ear and Hearing</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>3</NO>
<PG>191-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-02 16:07:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rovers MM, Straatman H, Ingels K, van der Wilt GJ, van den Broek P, Zielhuis GA</AU>
<TI>The effect of ventilation tubes on language development in infants with otitis media with effusion: a randomized trial</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>106</VL>
<NO>3</NO>
<PG>e42(1-8)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-08-02 16:08:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ah_x002d_Tye-2001" NAME="Ah-Tye 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;A part of the Paradise 2001 study.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ah-Tye C, Paradise JL, Colborn DK</AU>
<TI>Otorrhea in young children after tympanostomy-tube placement for persistent middle-ear effusion: prevalence, incidence, and duration</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>107</VL>
<NO>6</NO>
<PG>1251-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonding-1985" MODIFIED="2010-07-15 15:42:28 +0100" MODIFIED_BY="[Empty name]" NAME="Bonding 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-07-15 15:42:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;All right ears had ventilation tubes.&lt;/p&gt;" NOTES_MODIFIED="2010-07-15 15:42:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonding P, Tos M</AU>
<TI>Grommets versus paracentesis in secretory otitis media. A prospective, controlled study</TI>
<SO>American Journal of Otolaryngology</SO>
<YR>1985</YR>
<VL>6</VL>
<NO>6</NO>
<PG>455-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1978" MODIFIED="2010-07-13 09:40:51 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-07-13 09:40:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown MJKM, Richards SH, Ambegaokar AG</AU>
<TI>Grommets and glue ear: a five-year follow up of a controlled trial</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>1978</YR>
<VL>71</VL>
<NO>5</NO>
<PG>353-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bulman-1984" NAME="Bulman 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bulman CH, Brook SJ, Berry MG</AU>
<TI>A prospective randomized trial of adenoidectomy vs grommet insertion in treatment of glue ear</TI>
<SO>Clinical Otolaryngology and Allied Sciences</SO>
<YR>1984</YR>
<VL>9</VL>
<NO>2</NO>
<PG>67-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casselbrant-2009" MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" NAME="Casselbrant 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casselbrant ML, Mandel EM, Rockette HE, Kurs-Lasky M, Fall PA, Bluestone CD</AU>
<TI>Adenoidectomy for otitis media with effusion in 2-3-year-old children</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2009</YR>
<VL>73</VL>
<PG>1718-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2000" MODIFIED="2010-07-15 15:42:32 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-07-15 15:42:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DL, Swank PR, Owen MJ, Baldwin CD, Howie VM, McCormick DP</AU>
<TI>Effects of early middle ear effusion on child intelligence at three, five, and seven years of age</TI>
<SO>Journal of Pediatric Psychology</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>1</NO>
<PG>5-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koopman-2004" MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" NAME="Koopman 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koopman JP, Reuchlin AG, Kummer EE, Boumans LJJ, Rijntjes E, Hoeve LJ, et al</AU>
<TI>Laser myringotomy versus ventilation tubes in children with otitis media with effusion: randomized trial</TI>
<SO>Laryngoscope</SO>
<YR>2004</YR>
<VL>114</VL>
<NO>5</NO>
<PG>844-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-1991" MODIFIED="2010-08-02 12:05:54 +0100" MODIFIED_BY="[Empty name]" NAME="Le 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-08-02 12:05:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le CT, Freeman DW, Fireman BH</AU>
<TI>Evaluation of ventilating tubes and myringotomy in the treatment of recurrent or persistent otitis media</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>1</NO>
<PG>2-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lildholdt-1983" MODIFIED="2010-07-15 15:42:35 +0100" MODIFIED_BY="[Empty name]" NAME="Lildholdt 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-07-15 15:42:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lildholdt T</AU>
<TI>Ventilation tubes in secretory otitis media. A randomized, controlled study of the course, the complications, and the sequelae of ventilation tubes</TI>
<SO>Acta Oto-Laryngologica. Supplementum</SO>
<YR>1983</YR>
<VL>398</VL>
<PG>1-28</PG>
<CY>Stockh.</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandel-1989" MODIFIED="2010-08-02 12:07:44 +0100" MODIFIED_BY="[Empty name]" NAME="Mandel 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-08-02 12:07:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Too complicated to include in the review&lt;/p&gt;" NOTES_MODIFIED="2010-08-02 12:07:44 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandel EM, Rockette HE, Bluestone CD, Paradise JL, Nozza RJ</AU>
<TI>Myringotomy with and without tympanostomy tubes for chronic otitis media with effusion</TI>
<SO>Archives of Otolaryngology - Head &amp; Neck Surgery</SO>
<YR>1989</YR>
<VL>115</VL>
<NO>10</NO>
<PG>1217-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paradise-1997" MODIFIED="2010-08-02 16:07:48 +0100" MODIFIED_BY="[Empty name]" NAME="Paradise 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-08-02 16:07:48 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Observational study focusing on adenoidectomy&lt;/p&gt;" NOTES_MODIFIED="2010-08-02 16:07:48 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paradise JL, Rockette HE, Colborn DK, Bernard BS, Smith CG, Kurs-Lasky M, et al</AU>
<TI>Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>99</VL>
<NO>3</NO>
<PG>318-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richards-1971" MODIFIED="2010-08-02 16:07:55 +0100" MODIFIED_BY="[Empty name]" NAME="Richards 1971" YEAR="1971">
<REFERENCE MODIFIED="2010-08-02 16:07:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richards SH, Shaw JD, Kilby D, Campbel H</AU>
<TI>Grommets and glue ears: a clinical trial</TI>
<SO>Journal of Laryngology and Otology</SO>
<YR>1971</YR>
<VL>85</VL>
<NO>1</NO>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roydhouse-1980" MODIFIED="2010-08-02 16:08:02 +0100" MODIFIED_BY="[Empty name]" NAME="Roydhouse 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-08-02 16:08:02 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;All children had ventilation tubes, half had adenoidectomy&lt;/p&gt;" NOTES_MODIFIED="2010-08-02 16:08:02 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roydhouse N</AU>
<TI>Adenoidectomy for otitis media with mucoid effusion</TI>
<SO>Annals of Otology, Rhinology, and Laryngology</SO>
<YR>1980</YR>
<VL>89(3 Pt 2)</VL>
<PG>312-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schilder-1993" NAME="Schilder 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schilder AG, Van Manen JG, Zielhuis GA, Grievink EH, Peters SA, van den Broek P</AU>
<TI>Long-term effects of otitis media with effusion on language, reading and spelling</TI>
<SO>Clinical Otolaryngology and Allied Sciences</SO>
<YR>1993</YR>
<VL>18</VL>
<NO>3</NO>
<PG>234-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shishegar-2007" MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" NAME="Shishegar 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shishegar M, Hoghoghi H</AU>
<TI>Comparison of adenoidectomy and myringotomy with and without tube placement in the short term hearing status of children with otitis media with effusion: a preliminary report</TI>
<SO>Iranian Journal of Medical Sciences</SO>
<YR>2007</YR>
<VL>32</VL>
<NO>3</NO>
<PG>169-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-To-1984" MODIFIED="2010-07-13 09:41:03 +0100" MODIFIED_BY="[Empty name]" NAME="To 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-07-13 09:41:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>To SS, Pahor AL, Robin PE</AU>
<TI>A prospective trial of unilateral grommets for bilateral secretory otitis media in children</TI>
<SO>Clinical Otolaryngology and Allied Sciences</SO>
<YR>1984</YR>
<VL>9</VL>
<NO>2</NO>
<PG>115-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Rohail-2006" MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" NAME="Rohail 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rohail A, Gill ZI</AU>
<TI>A comparison of medical treatment versus surgical treatment for the management of otitis media with effusion</TI>
<SO>Annals of King Edward Medical College</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>1</NO>
<PG>64-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2010-07-07 10:27:25 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-09-07 13:15:25 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-09-07 13:15:25 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Caye_x002d_Thomasen-2008" MODIFIED="2010-07-23 12:22:37 +0100" MODIFIED_BY="[Empty name]" NAME="Caye-Thomasen 2008" TYPE="JOURNAL_ARTICLE">
<AU>Caye-Thomasen P, Stangerup SE,  Jorgensen G, Drozdziewic D, Bonding P, Tos M</AU>
<TI>Myringotomy versus ventilation tubes in secretory otitis media: eardrum pathology, hearing, and Eustachian tube function 25 years after treatment</TI>
<SO>Otology &amp; Neurotology</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>5</NO>
<PG>649-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Beer-2004" MODIFIED="2010-08-23 08:28:50 +0100" MODIFIED_BY="[Empty name]" NAME="de Beer 2004" TYPE="JOURNAL_ARTICLE">
<AU>de Beer BA, Snik AF, Schilder AGM, Zielhuis GA, Ingels K, Graamans K</AU>
<TI>Hearing loss in young adults who had ventilation tube insertion in childhood</TI>
<SO>Annals of Otology, Rhinology &amp; Laryngology</SO>
<YR>2004</YR>
<VL>113</VL>
<NO>6</NO>
<PG>438-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffin-2006" MODIFIED="2010-08-31 18:49:52 +0100" MODIFIED_BY="[Empty name]" NAME="Griffin 2006" TYPE="COCHRANE_REVIEW">
<AU>Griffin G, Flynn CA, Bailey RE, Schultz JK</AU>
<TI>Antihistamines and/or decongestants for otitis media with effusion (OME) in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-08-31 18:49:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-31 18:49:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD003423. DOI: 10.1002/14651858.CD003423.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Handbook-2009" MODIFIED="2010-08-24 20:41:18 +0100" MODIFIED_BY="[Empty name]" NAME="Handbook 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</TI>
<SO>The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-2001" MODIFIED="2010-08-02 16:09:00 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kay DJ, Nelson M, Rosenfeld RM</AU>
<TI>Meta-analysis of tympanostomy tube sequelae</TI>
<SO>Otolaryngology - Head and Neck Surgery</SO>
<YR>2001</YR>
<VL>124</VL>
<PG>374-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2008" MODIFIED="2010-08-02 15:44:15 +0100" MODIFIED_BY="[Empty name]" NAME="NICE 2008" TYPE="OTHER">
<AU>National Collaborating Centre for Women&#8217;s and Children&#8217;s Health (Commissioned by the National Institute for Health and Clinical Excellence)</AU>
<TI>Surgical management of otitis media with effusion in children</TI>
<SO>http://guidance.nice.org.uk/CG60/Guidance/pdf/English</SO>
<YR>February 2008 (accessed 2 August 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perera-2006" MODIFIED="2010-08-25 16:04:21 +0100" MODIFIED_BY="[Empty name]" NAME="Perera 2006" TYPE="COCHRANE_REVIEW">
<AU>Perera R, Haynes J, Glasziou PP, Heneghan CJ</AU>
<TI>Autoinflation for hearing loss associated with otitis media with effusion</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-08-25 16:04:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-25 16:04:21 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD006285. DOI: 10.1002/14651858.CD006285"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2010-07-06 14:25:37 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rovers-2005" MODIFIED="2010-08-03 13:56:09 +0100" MODIFIED_BY="[Empty name]" NAME="Rovers 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rovers MM, Black N, Browning GG, Maw R, Zielhuis GA, Haggard MP</AU>
<TI>Grommets in otitis media with effusion: an individual patient data meta-analysis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2005</YR>
<VL>90</VL>
<NO>5</NO>
<PG>480-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2006" MODIFIED="2010-09-02 13:50:00 +0100" MODIFIED_BY="[Empty name]" NAME="Thomas 2006" TYPE="COCHRANE_REVIEW">
<AU>Thomas CL, Simpson SA, Butler CC, van der Voort J, Lewis R</AU>
<TI>Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-09-02 13:50:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-02 13:50:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD001935. DOI: 10.1002/14651858.CD001935.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-den-Aardweg-2010" MODIFIED="2010-07-06 14:07:12 +0100" MODIFIED_BY="[Empty name]" NAME="van den Aardweg 2010" TYPE="COCHRANE_REVIEW">
<AU>van den Aardweg MTA, Schilder AGM, Herkert E, Boonacker CWB, Rovers MM</AU>
<TI>Adenoidectomy for otitis media in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-07-06 14:07:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-07-06 14:07:12 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD007810. DOI: 10.1002/14651858.CD007810.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Williamson-2009" MODIFIED="2010-09-07 13:09:32 +0100" MODIFIED_BY="[Empty name]" NAME="Williamson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Williamson I, Benge S, Barton S, Petrou S, Letley L, Fasey N, et al</AU>
<TI>Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b4984</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williamson-2010" MODIFIED="2010-08-31 18:43:13 +0100" MODIFIED_BY="[Empty name]" NAME="Williamson 2010" TYPE="JOURNAL_ARTICLE">
<AU>Williamson I</AU>
<TI>Otitis media with effusion</TI>
<SO>Clinical Evidence</SO>
<YR>2010</YR>
<VL>Jun</VL>
<PG>119-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zielhuis-1990" NAME="Zielhuis 1990" TYPE="JOURNAL_ARTICLE">
<AU>Zielhuis GA, Rach GH, van-den-Broek P</AU>
<TI>The occurrence of otitis media with effusion in Dutch pre-school children</TI>
<SO>Clinical Otolaryngology and Allied Sciences</SO>
<YR>1990</YR>
<VL>15</VL>
<NO>2</NO>
<PG>147-53</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-09-02 13:47:28 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Lous-2005" MODIFIED="2010-09-02 13:47:27 +0100" MODIFIED_BY="[Empty name]" NAME="Lous 2005" TYPE="COCHRANE_REVIEW">
<AU>Lous J, Burton MJ, Felding J, Ovesen T, Rovers M, Williamson I</AU>
<TI>Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-09-02 13:47:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-02 13:47:27 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD001801. DOI: 10.1002/14651858.CD001801.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-09-07 13:03:22 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-09-07 13:00:39 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-08-31 18:28:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black-1990">
<CHAR_METHODS MODIFIED="2010-07-15 13:24:01 +0100" MODIFIED_BY="[Empty name]">
<P>RCT (randomised by ears)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 12:56:42 +0100" MODIFIED_BY="[Empty name]">
<P>149 children undergoing surgery for bilateral OME on the basis of 'clinical judgement'</P>
<P>Age 4 to 9 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-31 18:28:50 +0100" MODIFIED_BY="[Empty name]">
<P>Shepard ventilation tube in one ear versus myringotomy in the other ear; half had adenoidectomy (data from the adenoidectomy arm are not included in this review)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-27 15:17:31 +0100" MODIFIED_BY="[Empty name]">
<P>At 7 weeks, 6, 12 and 24 months:</P>
<P>Hearing (mean hearing loss of 3 worst-heard frequencies)<BR/>Tympanometry<BR/>Parents' opinion<BR/>Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-15 13:24:22 +0100" MODIFIED_BY="[Empty name]">
<P>73% middle ear effusion</P>
<P>24% of treated ears without OME at operation</P>
<P>Unilateral tube study</P>
<P>All had myringotomy in control ears</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-31 18:28:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dempster-1993">
<CHAR_METHODS MODIFIED="2010-08-31 18:28:54 +0100" MODIFIED_BY="[Empty name]">
<P>RCT (randomised by ears); unilateral Shepard grommets</P>
<P>RCT (randomised by children); adenoidectomy versus no adenoidectomy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-15 13:27:25 +0100" MODIFIED_BY="[Empty name]">
<P>78 children referred for hearing loss; bilateral OME for 3 months or more</P>
<P>Age 3 to 12 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-15 11:47:36 +0100" MODIFIED_BY="[Empty name]">
<P>All had tube in one ear versus no surgery</P>
<P>37 had adenoidectomy, 35 had no adenoidectomy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-15 11:51:15 +0100" MODIFIED_BY="[Empty name]">
<P>Mean hearing loss at 6 and 12 months<BR/>Tympanometry<BR/>Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-15 13:27:51 +0100" MODIFIED_BY="[Empty name]">
<P>100% middle ear effusion at surgery</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 12:53:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gates-1987">
<CHAR_METHODS MODIFIED="2010-08-17 20:34:02 +0100" MODIFIED_BY="[Empty name]">
<P>RCT (randomised by children) Shepard grommets versus no grommets</P>
<P>RCT (randomised by children) adenoidectomy versus no adenoidectomy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>491 children referred with at least 2 months unilateral or bilateral OME</P>
<P>Age 4 to 8 years</P>
<P>All treated with an antibiotic and decongestant before inclusion</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-07 12:52:45 +0100" MODIFIED_BY="[Empty name]">
<P>1) Myringotomy only, 2) grommets only, 3) adenoidectomy and myringotomy, and 4) adenoidectomy and grommets</P>
<P>255 had adenoidectomy and 236 had no adenoidectomy</P>
<P>125 and 129 had grommets; 130 and 107 had no grommets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>Time with effusion (otoscopy and tympanometry)<BR/>Time with hearing loss <U>&gt;</U> 20 dB (3 frequency pure tone average)<BR/>Surgical retreatments<BR/>Complications<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-07 12:53:16 +0100" MODIFIED_BY="[Empty name]">
<P>298 bilateral OME, 123 unilateral OME, and 70 had no OME</P>
<P>27 children (6%) received a treatment other than the one assigned</P>
<P>Many children also had acute otitis media</P>
<P>See also Gates 1989 (<LINK REF="STD-Gates-1987" TYPE="STUDY">Gates 1987</LINK> for reference) which adds no additional audiometric or other data pertinent to this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 20:34:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mandel-1992">
<CHAR_METHODS MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>Balanced RCT (randomised by children); 3 groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>111 children referred for OME; all with unilateral or bilateral OME for 2 months or more (n = 37, 39, 35); mean hearing level in worst ear 24 dB</P>
<P>Age 7 months to 12 years</P>
<P>59% had bilateral OME at randomisation</P>
<P>All treated with antibiotics for 2 weeks before inclusion</P>
<P>Children with a mean hearing level &gt; 35 dB excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 20:34:27 +0100" MODIFIED_BY="[Empty name]">
<P>Bilateral Armstrong grommets versus bilateral myringotomy versus no surgery</P>
<P>None had adenoidectomy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>Hearing SRT<BR/>SAT<BR/>Treatment failure in first year<BR/>Days with OME<BR/>Episodes of AOM<BR/>Episodes of otorrhoea</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-15 12:19:14 +0100" MODIFIED_BY="[Empty name]">
<P>Balanced by age and duration of OME</P>
<P>High cross-over makes assessment difficult</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 12:55:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maw-1979_x002d_86">
<CHAR_METHODS MODIFIED="2010-08-17 20:34:52 +0100" MODIFIED_BY="[Empty name]">
<P>RCT (randomised by ears); unilateral Shepard tube<BR/>RCT (randomised by children); adenotonsillectomy versus adenoidectomy versus neither</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-15 13:31:42 +0100" MODIFIED_BY="[Empty name]">
<P>150 children referred with long-standing bilateral OME (mean duration 18 months) with symmetrical hearing loss in excess of 25 dB HL</P>
<P>Age 2 to 9 years </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 22:03:49 +0100" MODIFIED_BY="[Empty name]">
<P>All had unilateral Shepard tube; 47 had tonsillectomy, 47 had adenoidectomy and 56 had neither</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>Hearing (mean of frequencies tested dB and change in mean hearing threshold)<BR/>Effusion resolved</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-07 12:55:21 +0100" MODIFIED_BY="[Empty name]">
<P>13 patients (8%) excluded at operation because no fluid found at myringotomy or because contralateral ear suspected to be dry</P>
<P>See Maw 1993 and Maw 1994 (<LINK REF="STD-Maw-1979_x002d_86" TYPE="STUDY">Maw 1979-86</LINK> for references) for long-term results; not all data available at all time points for each ear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 12:55:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maw-1999">
<CHAR_METHODS MODIFIED="2010-07-15 13:34:31 +0100" MODIFIED_BY="[Empty name]">
<P>RCT (randomised by children)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>182 children with bilateral OME, disruption in speech, language or behaviour, and hearing loss (25 dB or poorer at 4000 Hz only) for at least 3 months, referred to hospital</P>
<P>Mean age 2.9 years </P>
<P>83 + 73 = 156 completed the trial</P>
<P>Children with congenital syndromes were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-24 10:54:12 +0100" MODIFIED_BY="[Empty name]">
<P>Bilateral Shepard or Shah grommets versus 'watchful waiting/active monitoring' (9 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>Hearing<BR/>Verbal comprehension<BR/>Expressive language (Reynell Expressive Language Scales - revised)<BR/>Retreatment surgery<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-07 12:55:47 +0100" MODIFIED_BY="[Empty name]">
<P>18 children did not receive the randomised treatment</P>
<P>See also Wilks 2000 and Hall 2009 (<LINK REF="STD-Maw-1999" TYPE="STUDY">Maw 1999</LINK> for references)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 12:56:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MRC_x003a_-TARGET-2001">
<CHAR_METHODS MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>RCT (randomised by child); 3 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-07 12:56:04 +0100" MODIFIED_BY="[Empty name]">
<P>376 children qualified on 2 occasions, 3 months apart, with better ear hearing level &gt; 20 dB HL with tympanometrically confirmed bilateral otitis media with effusion</P>
<P>Age aged 3.5 to 7 years</P>
<P>Children with a hearing loss of 40 dB or greater in their better hearing ear were not obliged to be randomised</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 20:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>'Watchful waiting/active monitoring' versus bilateral Shepard grommets versus bilateral grommets with adenoidectomy</P>
<P>376 children were randomised: 122 to further 'watchful waiting/active monitoring', 126 to bilateral grommets and 128 to bilateral grommets with adenoidectomy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-07 12:56:19 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up 3, 6, 12, 18 and 24 months</P>
<P>Binaural mean hearing level<BR/>Reported hearing difficulty<BR/>Quality of life (parent and child)<BR/>Behaviour<BR/>General health<BR/>OM8-30<BR/>Repeat/revision surgery<BR/>Adverse otoscopic effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-12 12:58:55 +0100" MODIFIED_BY="[Empty name]">
<P>No peer reviewed paper reporting any of the above outcomes has been published despite the trial being completed by 2000</P>
<P>Limited data have been made available for meta-analysis for this review</P>
<P>Good follow up</P>
<P>High proportion of cross-over to surgery from 'watchful waiting/active monitoring'; 43% in the first year and 57% by the end of the second year</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 12:56:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paradise-2001">
<CHAR_METHODS MODIFIED="2010-07-15 12:37:24 +0100" MODIFIED_BY="[Empty name]">
<P>RCT (randomised by children) after screening 6350 children for OME</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>588 children (9.2%) met the inclusion criteria; 429 randomised: 216 and 213</P>
<P>Age 0 to 3 years</P>
<P>18% had bilateral effusion for 90 days; 16% unilateral effusion for 135 days or intermittent effusion (19% bilateral; 47% unilateral) for specified longer periods</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 20:47:20 +0100" MODIFIED_BY="[Empty name]">
<P>Early or delayed (up to 9 months) insertion of Teflon bi-flanged grommets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-07 12:56:46 +0100" MODIFIED_BY="[Empty name]">
<P>Days with OME<BR/>Hearing<BR/>Developmental testing (cognition (McCarthy Scale of Children's Abilities), receptive language (Peabody Picture Vocabulary Test-Revised), expressive language (Number of Different Words, Mean Length of Utterance in Morphemes, Percentage of Consonants Correct-Revised) at 3 years<BR/>Reports of parental stress (Parents Stress Index) and child behaviour (Child Behaviour Checklist)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-07 12:56:59 +0100" MODIFIED_BY="[Empty name]">
<P>402 underwent developmental testing</P>
<P>37 + 66 children did not receive the randomised treatment</P>
<P>63% had unilateral OME and 66% discontinuous OME</P>
<P>See also Paradise 2003 (3 papers), 2004, 2005, 2006, 2007 (<LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK> for references)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 12:57:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rach-1991">
<CHAR_METHODS MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>Balanced RCT (randomised by children) after screening 1439 children for OME</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-15 12:50:31 +0100" MODIFIED_BY="[Empty name]">
<P>288 children (20%) met the screening criteria; 84 (5.8%) were eligible for the trial; only 52 children were randomised; 43 completed</P>
<P>Age 2 to 4 years; mean 39 months</P>
<P>Non-Dutch speaking children and children with multiple illnesses and cognitive defects were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 22:02:04 +0100" MODIFIED_BY="[Empty name]">
<P>Bilateral Donaldson grommets versus no surgery ('watchful waiting/active monitoring' for at least 9 months)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>Verbal comprehension at 6 months<BR/>Expressive language at 6 months (Dutch version of Reynell Developmental Language Scales - revised)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-07 12:57:26 +0100" MODIFIED_BY="[Empty name]">
<P>Balanced allocation on age, gender, treatment hospital and result of first language test</P>
<P>Some results published in Zielhuis 1989 (see <LINK REF="STD-Rach-1991" TYPE="STUDY">Rach 1991</LINK> for reference)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 12:57:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rovers-2000">
<CHAR_METHODS MODIFIED="2010-07-15 12:54:58 +0100" MODIFIED_BY="[Empty name]">
<P>Balanced RCT (randomised by children) after screening</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>30,099 invited for screening, 386 (1.3%) had at least 4 to 6 months with OME</P>
<P>187 children who had failed 3 successive hearing screening tests with persistent (4 to 6 months) bilateral OME confirmed by tympanometry and otoscopy were randomised</P>
<P>Age 16 to 24 months (mean 19 months at randomisation)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 20:46:20 +0100" MODIFIED_BY="[Empty name]">
<P>Bilateral Bevel Bobbins grommets versus 'watchful waiting/active monitoring'</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>Hearing loss<BR/>Verbal comprehension (Reynell) and expressive language (Schlichting) both expressed as mean language development in months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-07 12:57:57 +0100" MODIFIED_BY="[Empty name]">
<P>Balanced allocation on age, gender, season, mother's education and hospital</P>
<P>Follow up at 6 and 12 months</P>
<P>At 12 months 3 children in the grommets group and 8 children in the 'watchful waiting/active monitoring' group were lost to follow up</P>
<P>10 children in the 'watchful waiting/active monitoring' group received grommets during the year</P>
<P>More detailed information about the effect of grommets on hearing and quality of life is published in 2 later papers (2001)</P>
<P>Details on otorrhoea are reported in a later paper (Ingels 2005 - see <LINK REF="STD-Rovers-2000" TYPE="STUDY">Rovers 2000</LINK> for reference)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AOM: acute otitis media; OME: otitis media with effusion; SAT: speech awareness threshold; SRT: speech recognition threshold; RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-09-07 13:03:13 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-07-30 09:45:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ah_x002d_Tye-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-30 09:45:06 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: </P>
<P>Not a randomised controlled trial. Analysis of prevalence, incidence and duration of otorrhoea in the grommet-treated group in study <LINK REF="STD-Paradise-2001" TYPE="STUDY">Paradise 2001</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-30 09:45:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bonding-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-30 09:45:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: </P>
<P>Non-randomised study; all right ears had grommets</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-02 11:51:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-02 11:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Randomisation of ears unclear</P>
<P>Participants:</P>
<P>60 children with bilateral OME</P>
<P>Interventions:</P>
<P>All children had adenoidectomy whereas we were interested in grommets versus 'watchful waiting/active monitoring'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-02 11:58:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bulman-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-02 11:58:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Randomised; not concealed</P>
<P>Participants:</P>
<P>Not all participants had bilateral OME. Only 6 weeks with preoperative middle ear effusion.</P>
<P>Interventions:</P>
<P>Adenoidectomy versus no adenoidectomy (by child); paracentesis only versus grommet (by ears)</P>
<P>Outcome measures:</P>
<P>Results in different groups impossible to differentiate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-07 13:02:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casselbrant-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-07 13:02:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Randomised</P>
<P>Participants:</P>
<P>Children 24 to 47 months of age, with a history of bilateral middle ear effusion for at least 3 months, unilateral for 6 months or longer or unilateral for 3 months after extrusion of a tympanostomy tube, unresponsive to recent antibiotic</P>
<P>Intervention:</P>
<P>The comparison was adenoidectomy with myringotomy and grommets versus adenoidectomy with myringotomy alone and myringotomy and grommets, i.e. the effect of grommets versus 'watchful waiting/active monitoring' could not be studied. Comparison of adenoidectomy versus grommets is the aim of another Cochrane Review (<LINK REF="REF-van-den-Aardweg-2010" TYPE="REFERENCE">van den Aardweg 2010</LINK>).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-07 13:02:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-07 13:02:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Originally designed as a RCT, but changed to an observational cohort study because of parental resistance to randomise the children. 698 enrolled at birth, 379 assessed at the age of 3 and 198 at the age of 7 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-07 13:02:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koopman-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-07 13:02:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Randomised</P>
<P>Participants:</P>
<P>208 children 24 to 47 months of age, with a history of bilateral middle ear effusion for at least 3 months, unilateral for 6 months or longer or unilateral for 3 months after extrusion of a tympanostomy tube, unresponsive to recent antibiotic</P>
<P>Intervention:</P>
<P>The comparison was laser myringotomy versus grommets. A 'watchful waiting/active monitoring' group is lacking. Furthermore, the aim was to study whether laser was effective and therefore it might not be comparable to conventional myringotomy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-07 13:02:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-07 13:02:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Randomised (by ears)</P>
<P>Participants: </P>
<P>Unilateral treatment with ventilation tube in 13 children with bilateral persistent middle ear effusion and 44 children with bilateral recurrent acute otitis media. Data from the 2 groups are impossible to separate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-02 16:00:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lildholdt-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-02 16:00:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Inadequately randomised and inadequate concealment (randomised by birthday)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-02 12:09:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mandel-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-02 12:09:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Randomised</P>
<P>Participants: </P>
<P>Study included middle ear effusion and recurrent acute otitis media. Data could not be separated. Five different treatment groups: 3 without hearing loss and 2 with hearing loss.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-30 09:48:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paradise-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-30 09:48:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: </P>
<P>Non-randomised observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-02 12:11:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richards-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-02 12:11:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Randomised (by ears)</P>
<P>Participants:</P>
<P>57 children (aged 4 to 12 years) with bilateral OME</P>
<P>Interventions:</P>
<P>All children had adenoidectomy whereas we were interested in grommets versus 'watchful waiting/active monitoring'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-30 09:49:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roydhouse-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-30 09:49:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: </P>
<P>Non-randomised, case-control study (concerning the grommets)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-02 12:14:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schilder-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-02 12:14:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Randomised</P>
<P>Participants:</P>
<P>47 children (aged 7 to 8 years) with OME</P>
<P>Interventions:</P>
<P>Almost all children randomised to 'watchful waiting/active monitoring' at the age of 4 years were treated with grommets before the age of 8 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-02 12:15:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shishegar-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-02 12:15:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Randomised (by ear)</P>
<P>Participants:</P>
<P>30 children (aged 4 to 8 years) with OME</P>
<P>Interventions:</P>
<P>All children had adenoidectomy whereas we were interested in grommets versus 'watchful waiting/active monitoring'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-02 12:16:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-To-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-02 12:16:42 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:</P>
<P>Randomised (by ear)</P>
<P>Participants:</P>
<P>54 children (aged 47 months to 14 years) with OME</P>
<P>Interventions:</P>
<P>All children had adenoidectomy whereas we were interested in grommets versus 'watchful waiting/active monitoring'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>OME: otitis media with effusion</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-09-07 13:03:22 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-09-07 13:03:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rohail-2006">
<CHAR_METHODS MODIFIED="2010-09-07 13:03:22 +0100" MODIFIED_BY="[Empty name]">
<P>Described as "random allocation" but method not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-02 16:03:40 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients up to 12 years of age; inclusion criteria not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-02 16:05:00 +0100" MODIFIED_BY="[Empty name]">
<P>Medical versus surgical treatment - not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-02 16:05:36 +0100" MODIFIED_BY="[Empty name]">
<P>Resolution of OME, hearing, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-02 16:05:55 +0100" MODIFIED_BY="[Empty name]">
<P>ENT Department, Jinnah Hospital, Lahore, Pakistan</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-07-07 10:27:25 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-09-07 12:58:08 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Black-1990">
<DESCRIPTION>
<P>Shuffled non-numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:42:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dempster-1993">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:42:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gates-1987">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC_x003a_-TARGET-2001">
<DESCRIPTION>
<P>Computer-generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:42:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mandel-1992">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:43:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maw-1979_x002d_86">
<DESCRIPTION>
<P>Tables of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maw-1999">
<DESCRIPTION>
<P>Tables of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:43:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paradise-2001">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:44:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rach-1991">
<DESCRIPTION>
<P>Randomised balanced allocation procedure with a reference in a statistical journal</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:45:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rovers-2000">
<DESCRIPTION>
<P>Balanced allocation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-09-07 12:58:08 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:41:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-1990">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:42:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dempster-1993">
<DESCRIPTION>
<P>Serial numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gates-1987">
<DESCRIPTION>
<P>Allocation in blocks of 16 by statistician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC_x003a_-TARGET-2001">
<DESCRIPTION>
<P>Eligible children allocated by telephone from administrative office</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-07 12:55:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mandel-1992">
<DESCRIPTION>
<P>"Randomly assigned, within strata to..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maw-1979_x002d_86">
<DESCRIPTION>
<P>Sealed envelopes opened in theatre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maw-1999">
<DESCRIPTION>
<P>Sealed envelopes opened by third party</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-07 12:57:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paradise-2001">
<DESCRIPTION>
<P>In blocks by designated non-clinical staff</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-07 12:57:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rach-1991">
<DESCRIPTION>
<P>"the first 5 children were randomised; each subsequent child was allocated to the treatment group which would lead to the smallest imbalance..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-07 12:58:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rovers-2000">
<DESCRIPTION>
<P>Centrally located randomised list; allocation by telephone call to central location</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-1990">
<DESCRIPTION>
<P>Objective audiometric outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-08 10:42:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dempster-1993">
<DESCRIPTION>
<P>Objective hearing and tympanometric outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gates-1987">
<DESCRIPTION>
<P>Main outcome was time with effusion; an otoscopic diagnosis. Secondary outcomes of hearing and surgical treatments are objective</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC_x003a_-TARGET-2001">
<DESCRIPTION>
<P>Primary outcome objective pure tone thresholds</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-08 10:42:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mandel-1992">
<DESCRIPTION>
<P>Primary outcome was middle ear fluid defined using an algorithm of otoscopy and tympanometry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maw-1979_x002d_86">
<DESCRIPTION>
<P>Audiometry is the outcome reported in this review. Otoscopy for the presence of OME was not used in the analysis of time with effusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-08 10:43:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maw-1999">
<DESCRIPTION>
<P>Language outcomes and audiometry 'done masked of treatment'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-08 10:43:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paradise-2001">
<DESCRIPTION>
<P>Objective developmental tests</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-08 10:44:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rach-1991">
<DESCRIPTION>
<P>Objective language testing</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-08 10:45:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rovers-2000">
<DESCRIPTION>
<P>Language tests and hearing are objective measures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-09-07 12:57:11 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-29 22:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-1990">
<DESCRIPTION>
<P>85% seen at 12 months</P>
<P>61% seen at 24 months but these data are not reported in the review</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 09:01:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dempster-1993">
<DESCRIPTION>
<P>92% complete data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-07 12:53:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gates-1987">
<DESCRIPTION>
<P>A very high proportion of children (~60%) were not followed up. Only ~3% attended for more than 4 or more out of the potential 7 scheduled visits.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-21 13:23:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC_x003a_-TARGET-2001">
<DESCRIPTION>
<P>80% follow up at 2 years. Imputation of missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 09:13:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandel-1992">
<DESCRIPTION>
<P>87% follow up at 2 years</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-07 12:55:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maw-1979_x002d_86">
<DESCRIPTION>
<P>75% audiometry at 12 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:20:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maw-1999">
<DESCRIPTION>
<P>88% completed the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-07 12:57:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paradise-2001">
<DESCRIPTION>
<P>94% follow up when 3 years of age</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-08 10:44:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rach-1991">
<DESCRIPTION>
<P>No child appears to have been lost to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-27 15:17:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rovers-2000">
<DESCRIPTION>
<P>11 (6%) of 187 were lost to follow up in the first year</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-08-17 20:36:37 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-27 15:40:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-1990">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:42:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dempster-1993">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-02 11:36:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gates-1987">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 20:36:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MRC_x003a_-TARGET-2001">
<DESCRIPTION>
<P>Apart from hearing levels no 'by child' outcomes have been reported or made available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 09:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandel-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:43:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maw-1979_x002d_86">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-13 10:21:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maw-1999">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:44:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paradise-2001">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:44:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rach-1991">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:45:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rovers-2000">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-09-07 12:56:39 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-27 15:40:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-1990">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:42:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dempster-1993">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-02 11:36:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gates-1987">
<DESCRIPTION>
<P>A high proportion of the children had recurrent acute otitis media as evidenced by an 11% rate of otorrhoea in ears that had no grommet inserted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-07 12:56:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MRC_x003a_-TARGET-2001">
<DESCRIPTION>
<P>The time lapse since trial completion is 10 years. The reasons for the absence of peer reviewed publications have not been explained.</P>
<P>Cross-over from control arm is an intention-to-treat aspect and should not be considered a bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:42:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandel-1992">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:43:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maw-1979_x002d_86">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-07 12:55:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maw-1999">
<DESCRIPTION>
<P>The 18-month hearing data are not relevant as the design of the study was that 'watchful waiting/active monitoring' was only for 9 months. At 18 months 85% of these children had grommets. These data are not included in the review hence the data reported are free of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:44:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paradise-2001">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:44:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rach-1991">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 10:45:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rovers-2000">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2010-07-06 14:08:12 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-08-24 12:03:18 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-08-02 16:10:57 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Hearing levels by child</NAME>
<CONT_OUTCOME CHI2="2.3101941425771817" CI_END="-2.3934295217093027" CI_START="-5.996845821132812" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.195137671421057" ESTIMABLE="YES" I2="13.427189380332278" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2010-08-02 16:10:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3150269979637158" P_Q="1.0" P_Z="5.027806532175703E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.35391711005097454" TOTALS="YES" TOTAL_1="271" TOTAL_2="252" UNITS="" WEIGHT="100.0" Z="4.563624107205124">
<NAME>By child hearing levels at 6 to 9 months follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.19051392616359664" CI_START="-7.790513926163598" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" MEAN_1="25.7" MEAN_2="29.5" MODIFIED="2010-07-09 12:38:10 +0100" MODIFIED_BY="[Empty name]" ORDER="64" SD_1="10.9" SD_2="12.9" SE="2.036013905173902" STUDY_ID="STD-Maw-1999" TOTAL_1="79" TOTAL_2="63" WEIGHT="18.781517271675014"/>
<CONT_DATA CI_END="-3.1162813673200422" CI_START="-8.083718632679961" EFFECT_SIZE="-5.600000000000001" ESTIMABLE="YES" MEAN_1="17.5" MEAN_2="23.1" MODIFIED="2010-07-09 12:38:54 +0100" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="8.2" SD_2="10.1" SE="1.2672266696078167" STUDY_ID="STD-MRC_x003a_-TARGET-2001" TOTAL_1="106" TOTAL_2="105" WEIGHT="43.11866066801088"/>
<CONT_DATA CI_END="-0.12407652370777589" CI_START="-5.475923476292232" EFFECT_SIZE="-2.8000000000000043" ESTIMABLE="YES" MEAN_1="35.9" MEAN_2="38.7" MODIFIED="2010-07-09 13:13:00 +0100" MODIFIED_BY="[Empty name]" ORDER="66" SD_1="8.9" SD_2="8.9" SE="1.365292167304895" STUDY_ID="STD-Rovers-2000" TOTAL_1="86" TOTAL_2="84" WEIGHT="38.099822060314104"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0012646885382885" CI_END="1.5395743028254258" CI_START="-2.3654732123410023" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4129494547577881" ESTIMABLE="YES" I2="0.12630911214244592" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2010-08-02 16:10:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3170049394847896" P_Q="1.0" P_Z="0.6784911075651932" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0025261822428489194" TOTALS="YES" TOTAL_1="147" TOTAL_2="181" UNITS="" WEIGHT="100.0" Z="0.41452302724476486">
<NAME>By child hearing levels at 12 months follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.1465848270166825" CI_START="-2.1465848270166825" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="20.5" MODIFIED="2010-07-09 20:15:26 +0100" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="9.4" SD_2="10.1" SE="1.3503231936365188" STUDY_ID="STD-MRC_x003a_-TARGET-2001" TOTAL_1="110" TOTAL_2="100" WEIGHT="54.35252726211059"/>
<CONT_DATA CI_END="1.388254764743345" CI_START="-4.388254764743345" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="33.2" MEAN_2="34.7" MODIFIED="2010-07-09 20:15:58 +0100" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="7.2" SD_2="7.9" SE="1.473626447998805" STUDY_ID="STD-Rovers-2000" TOTAL_1="37" TOTAL_2="81" WEIGHT="45.6474727378894"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8944160490025055" CI_END="3.1826892055934786" CI_START="-3.2218006765218674" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.019555735464194392" ESTIMABLE="YES" I2="47.21328503701473" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2010-08-02 16:10:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.16870489934582467" P_Q="1.0" P_Z="0.990450131565564" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="2.5707633702654533" TOTALS="YES" TOTAL_1="148" TOTAL_2="135" UNITS="" WEIGHT="100.0" Z="0.011969270904165786">
<NAME>By child hearing levels at 18 months follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.83665100830919" CI_START="-5.636651008309187" EFFECT_SIZE="-1.8999999999999986" ESTIMABLE="YES" MEAN_1="19.6" MEAN_2="21.5" MODIFIED="2010-07-09 12:49:26 +0100" MODIFIED_BY="[Empty name]" ORDER="69" SD_1="8.7" SD_2="8.5" SE="1.9064896282704247" STUDY_ID="STD-Maw-1999" TOTAL_1="45" TOTAL_2="37" WEIGHT="43.016840468612"/>
<CONT_DATA CI_END="4.249554798598163" CI_START="-1.4495547985981592" EFFECT_SIZE="1.4000000000000021" ESTIMABLE="YES" MEAN_1="21.1" MEAN_2="19.7" MODIFIED="2010-07-09 12:49:41 +0100" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="10.2" SD_2="10.4" SE="1.4538812044890037" STUDY_ID="STD-MRC_x003a_-TARGET-2001" TOTAL_1="103" TOTAL_2="98" WEIGHT="56.98315953138799"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-08-24 12:03:18 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Hearing levels by ears</NAME>
<CONT_OUTCOME CHI2="21.490253639852142" CI_END="-1.0495635372436887" CI_START="-19.12035290201572" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.084958219629705" ESTIMABLE="YES" I2="90.69345558448346" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-08-02 16:11:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.1550481327681226E-5" P_Q="1.0" P_Z="0.0286961256143384" Q="0.0" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="57.79112018345932" TOTALS="YES" TOTAL_1="115" TOTAL_2="115" UNITS="" WEIGHT="100.0" Z="2.187636023758696">
<NAME>By ear hearing levels at 4 to 6 months follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.1147899448253886" CI_START="-10.485210055174612" EFFECT_SIZE="-5.800000000000001" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="24.8" MODIFIED="2010-07-09 13:00:23 +0100" MODIFIED_BY="[Empty name]" ORDER="71" SD_1="10.0" SD_2="10.0" SE="2.390457218668787" STUDY_ID="STD-Black-1990" TOTAL_1="35" TOTAL_2="35" WEIGHT="33.464734049661395"/>
<CONT_DATA CI_END="-0.13584424199640655" CI_START="-10.464155758003596" EFFECT_SIZE="-5.300000000000001" ESTIMABLE="YES" MEAN_1="15.8" MEAN_2="21.1" MODIFIED="2010-07-09 13:00:23 +0100" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="10.3" SD_2="11.7" SE="2.63482176138837" STUDY_ID="STD-Dempster-1993" TOTAL_1="35" TOTAL_2="35" WEIGHT="32.82990427602182"/>
<CONT_DATA CI_END="-14.504494089352622" CI_START="-23.495505910647378" EFFECT_SIZE="-19.0" ESTIMABLE="YES" MEAN_1="17.5" MEAN_2="36.5" MODIFIED="2010-07-09 13:00:23 +0100" MODIFIED_BY="[Empty name]" ORDER="73" SD_1="9.79" SD_2="11.87" SE="2.293667611296613" STUDY_ID="STD-Maw-1979_x002d_86" TOTAL_1="45" TOTAL_2="45" WEIGHT="33.70536167431678"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.570548808303142" CI_END="0.06827554105041944" CI_START="-10.428831747336734" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.1802781031431575" ESTIMABLE="YES" I2="73.58183599838281" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-08-02 16:11:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.02270265435000729" P_Q="1.0" P_Z="0.05305562589693304" Q="0.0" RANDOM="YES" SCALE="15.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="15.808015012375598" TOTALS="YES" TOTAL_1="117" TOTAL_2="117" UNITS="" WEIGHT="100.00000000000001" Z="1.9344678935108905">
<NAME>By ear hearing levels at 7 to 12 months follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2852100551746135" CI_START="-9.08521005517461" EFFECT_SIZE="-4.399999999999999" ESTIMABLE="YES" MEAN_1="21.6" MEAN_2="26.0" ORDER="58269" SD_1="10.0" SD_2="10.0" SE="2.390457218668787" STUDY_ID="STD-Black-1990" TOTAL_1="35" TOTAL_2="35" WEIGHT="33.319187566648814"/>
<CONT_DATA CI_END="4.308812855004475" CI_START="-5.908812855004469" EFFECT_SIZE="-0.7999999999999972" ESTIMABLE="YES" MEAN_1="17.6" MEAN_2="18.4" ORDER="58270" SD_1="11.2" SD_2="10.6" SE="2.6065850675329423" STUDY_ID="STD-Dempster-1993" TOTAL_1="35" TOTAL_2="35" WEIGHT="31.727105282320398"/>
<CONT_DATA CI_END="-5.647351884335694" CI_START="-14.152648115664302" EFFECT_SIZE="-9.899999999999999" ESTIMABLE="YES" MEAN_1="17.5" MEAN_2="27.4" ORDER="58271" SD_1="8.61" SD_2="12.13" SE="2.1697582961772004" STUDY_ID="STD-Maw-1979_x002d_86" TOTAL_1="47" TOTAL_2="47" WEIGHT="34.9537071510308"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-08-02 16:19:42 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Time with effusion</NAME>
<CONT_OUTCOME CHI2="20.316000116382725" CI_END="-0.16761853836345836" CI_START="-0.477381586923403" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3225000626434307" ESTIMABLE="YES" I2="90.15554248600732" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2010-07-09 20:22:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.8764969536364546E-5" P_Q="1.0" P_Z="4.482117224779041E-5" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.016407232313522875" TOTALS="YES" TOTAL_1="288" TOTAL_2="286" UNITS="" WEIGHT="100.0" Z="4.081109807845368">
<NAME>Time (proportion) with effusion in first year</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3304231967007608" CI_START="-0.6095768032992391" EFFECT_SIZE="-0.47" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="0.64" MODIFIED="2010-07-09 13:10:40 +0100" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="0.3" SD_2="0.3" SE="0.07121396331779724" STUDY_ID="STD-Mandel-1992" TOTAL_1="36" TOTAL_2="35" WEIGHT="29.073401441335715"/>
<CONT_DATA CI_END="-0.1447734733896019" CI_START="-0.2352265266103981" EFFECT_SIZE="-0.19" ESTIMABLE="YES" MEAN_1="0.29" MEAN_2="0.48" MODIFIED="2010-07-09 13:11:14 +0100" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="0.2" SD_2="0.21" SE="0.023075182486586063" STUDY_ID="STD-Paradise-2001" TOTAL_1="159" TOTAL_2="157" WEIGHT="36.86357282020387"/>
<CONT_DATA CI_END="-0.25400271351886294" CI_START="-0.425997286481137" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="0.7" MODIFIED="2010-07-09 13:11:37 +0100" MODIFIED_BY="[Empty name]" ORDER="79" SD_1="0.3" SD_2="0.3" SE="0.04387697282168073" STUDY_ID="STD-Rovers-2000" TOTAL_1="93" TOTAL_2="94" WEIGHT="34.06302573846042"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3846990756812507" CI_END="-0.08325902134334837" CI_START="-0.1691254050097237" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.12619221317653603" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2010-08-02 16:19:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5003990345893068" P_Q="1.0" P_Z="8.368544637895452E-9" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="222" TOTAL_2="204" UNITS="" WEIGHT="100.0" Z="5.760861990331264">
<NAME>Time (proportion) with effusion in first two years</NAME>
<GROUP_LABEL_1>Treatment (tubes)</GROUP_LABEL_1>
<GROUP_LABEL_2>Control (no tubes)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.07707863001600503" CI_START="-0.20292136998399501" EFFECT_SIZE="-0.14" ESTIMABLE="YES" MEAN_1="0.35" MEAN_2="0.49" ORDER="58284" SD_1="0.24" SD_2="0.25" SE="0.032103329693969236" STUDY_ID="STD-Gates-1987" TOTAL_1="129" TOTAL_2="107" WEIGHT="46.55753881859973"/>
<CONT_DATA CI_END="-0.04042319670076086" CI_START="-0.3195768032992391" EFFECT_SIZE="-0.18" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="0.51" ORDER="58285" SD_1="0.3" SD_2="0.3" SE="0.07121396331779724" STUDY_ID="STD-Mandel-1992" TOTAL_1="36" TOTAL_2="35" WEIGHT="9.461497061370164"/>
<CONT_DATA CI_END="-0.03526177253447017" CI_START="-0.1647382274655299" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.4" ORDER="58286" SD_1="0.18" SD_2="0.18" SE="0.03303031483036257" STUDY_ID="STD-Paradise-2001" TOTAL_1="57" TOTAL_2="62" WEIGHT="43.9809641200301"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-08-02 16:11:44 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Language development</NAME>
<CONT_OUTCOME CHI2="3.959003479941743" CI_END="0.3896996968194391" CI_START="-0.20862476522771717" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.09053746579586097" ESTIMABLE="YES" I2="49.48223687771474" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2010-08-02 16:11:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13813823363946176" P_Q="1.0" P_Z="0.5530760882110439" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.03398979244353036" TOTALS="YES" TOTAL_1="202" TOTAL_2="192" UNITS="" WEIGHT="100.00000000000001" Z="0.5931570024874865">
<NAME>Comprehensive language development (measured with the Reynell test) at 6 to 9 months follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6166383835751756" CI_START="-3.9659786082724136E-4" EFFECT_SIZE="0.3081208928571742" ESTIMABLE="YES" MEAN_1="-0.04" MEAN_2="-0.35" ORDER="58292" SD_1="1.02" SD_2="0.98" SE="0.15740977546095133" STUDY_ID="STD-Maw-1999" TOTAL_1="87" TOTAL_2="77" WEIGHT="39.644155325300176"/>
<CONT_DATA CI_END="0.6996481787530613" CI_START="-0.49708536943926557" EFFECT_SIZE="0.10128140465689789" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="0.11" ORDER="58293" SD_1="0.61" SD_2="0.55" SE="0.305294780320457" STUDY_ID="STD-Rach-1991" TOTAL_1="22" TOTAL_2="21" WEIGHT="18.31674693597544"/>
<CONT_DATA CI_END="0.1675865359465978" CI_START="-0.4062496892527341" EFFECT_SIZE="-0.11933157665306812" ESTIMABLE="YES" MEAN_1="-0.06" MEAN_2="0.06" ORDER="58294" SD_1="0.95" SD_2="1.05" SE="0.14638948208377264" STUDY_ID="STD-Rovers-2000" TOTAL_1="93" TOTAL_2="94" WEIGHT="42.03909773872439"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.571189893466933" CI_END="0.4851458382187328" CI_START="-0.42452744580620705" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0303091962062629" ESTIMABLE="YES" I2="79.1039565376803" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2010-08-02 16:11:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.008349194513078362" P_Q="1.0" P_Z="0.8960860594793425" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.12715167179871154" TOTALS="YES" TOTAL_1="202" TOTAL_2="191" UNITS="" WEIGHT="100.00000000000003" Z="0.13060718393705112">
<NAME>Expressive language development (measured with Reynell, Schlichting) at 6 to 9 months follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7675493191615299" CI_START="-0.007549319161529844" EFFECT_SIZE="0.38" ESTIMABLE="YES" MEAN_1="-0.62" MEAN_2="-1.0" MODIFIED="2010-07-09 13:22:45 +0100" MODIFIED_BY="[Empty name]" ORDER="80" SD_1="1.27" SD_2="1.25" SE="0.19773287785820015" STUDY_ID="STD-Maw-1999" TOTAL_1="87" TOTAL_2="76" WEIGHT="32.39314762984518"/>
<CONT_DATA CI_END="0.5261079874733866" CI_START="-0.30610798747338663" EFFECT_SIZE="0.10999999999999999" ESTIMABLE="YES" MEAN_1="0.29" MEAN_2="0.18" MODIFIED="2010-07-09 13:22:45 +0100" MODIFIED_BY="[Empty name]" ORDER="81" SD_1="0.75" SD_2="0.64" SE="0.21230389474275718" STUDY_ID="STD-Rach-1991" TOTAL_1="22" TOTAL_2="21" WEIGHT="31.269395327911553"/>
<CONT_DATA CI_END="-0.06562000763711312" CI_START="-0.6343799923628868" EFFECT_SIZE="-0.35" ESTIMABLE="YES" MEAN_1="-0.18" MEAN_2="0.17" MODIFIED="2010-07-09 13:22:45 +0100" MODIFIED_BY="[Empty name]" ORDER="82" SD_1="1.19" SD_2="0.74" SE="0.14509449898367519" STUDY_ID="STD-Rovers-2000" TOTAL_1="93" TOTAL_2="94" WEIGHT="36.33745704224329"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-09-07 13:12:50 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-09-07 13:09:54 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-09-07 13:09:58 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="ROB - JB 070910.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-09-07 13:12:50 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>'Risk of bias' summary for follow-up papers.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-08-02 16:10:51 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Hearing levels by child, outcome: 1.1 By child hearing levels at 6 to 9 months follow up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-08-02 16:10:55 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Hearing levels by child, outcome: 1.2 By child hearing levels at 12 months follow up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2010-08-02 16:11:13 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Hearing levels by ears, outcome: 2.1 By ear hearing levels at 4 to 6 months follow up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2010-08-02 16:11:16 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-002.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Hearing levels by ears, outcome: 2.2 By ear hearing levels at 7 to 12 months follow up.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuwAAACgCAMAAABg+8nwAAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///80TKWtAAAhRklEQVR42u1de3AcR5n/VtpRz0qWtKuVbEmWJT8UhQMTCsmJo4eBxE5yxIJU4YSDcHGlqOLuj6QgVdwZOHJ5gKkQ7lLH4wgQAiGVS9XlyNMoIVxijsRa2VYsBXI+AkKyLMWWbVlvS9ppraS9nvf7sdrRamX1L5F3trvn+775+puer3t/MxNAQEGxNpBDXUBBg52CggY7BcXqRG4wSw1rrePRY1FTHYzb79b1wqwv6rtGz90wcfxRg2Zm1mBjT6Z80b/YNVRnr460GM4vucRbtJHJK4owqHB2hXrN3dILrVOCpZU3nlsXJn8ZszRrR/a2NvHPjKsaHXa7f6cv2if3vHn+7Ws+ZtR87Yq5YwN80sVf53M+HOA9NtN04b2ZpvPvrZSl866WXnhTtHQWnz8TJ380jZEHgtbSUuBCkXA5B0xZOBLtKiaFpLgqGqmojOyrAu6+cCTEkZJnoiUbI3ylDyhvzmfPtI2QjUi4greiqjTyTFjUvD4KcF8kUp5JN6A5mOPXzThiz30c1JSFwyVd0jFLTdgCKCUl4Ra4tZz8sYpfiL06HxEh4UgpI8vyGR1lkOjgLdX2GdEciJZUyZbmQxkpiRArK5p5S4k95bx1ZSWgbAvtufsi4ehJWdblm8YA1EEP/88fEouPt4yOfOwr0yWvfn/hY2feqIM2Unxm4rrKs5ObT8V/Fhhjmg5M18EToR3943ylDyisPnKQ/6zY8eMX66cv1cHZv7z1owlR8+/HDlYERl/suzQtWJgRTxxdiLNnNkLP4zt+/FLyK9PBUe7CW9/ixGOOS7668F+nSck7xEiON1TxC7GXbL8yKPso/viO0VDDcPxnO37+PJHls6V3vxZHD/+ZWKrts2N1MJW/45Rq6UePaS3dMZpXz1v3+MMHlW2hPbH7L53fjEuy1sAENZ6Aq6EvDhhG9pUXwZNS8esJ4W8BOOjtgzlS0j8Ai34pbQZW+MRQ1Ad8H/UXQ1I2iCU6+4pIXebANDJNDPmcg6Jeon10U/nnBXu0x8xCQLuL4hfB3t7tqo8w9A20jZEPlpflM4oaa5qKyKfcZzlSn72us/QXekv7eonHAbaz6rbQnthd3DYqy1oDwU6i7gjceis59I0fXDwlOILHdvFvF+lzUrkgNmzxS2m7FAULfAeAXjjZTAK7XdCZKfwRwuSPt+ert5KPjVctviXYoz1mQ9xq/aL3kXQmC7KSflt6AO4lf2qf3Sf12XZ7S4Fvelhj6WG5vWSpJGttLD3mwLNtbRMwA4MWv/cG+MpJnzXmwZVilgccpx8wBdzJF+/JoAeKY4lYsWAPOdhxmIZBcwJVCEE7v+h9FBOjLVf0qs8YiB2IDbj02ZXEvzqohgR0RtWKlub4ZOmqCPY82Mq0lhJbr+xWPaCO/NsmSaW+I9O+nMTu5aqI1Dzo3iZlNJrxHp6Bbd3QkUkXMC2M6InumtYyEqeCJ3TgIjBi5xe9j4RvUVmW75Y2M+Y+01t6L/zaZGlUmolrtnk/14qWCrLWRrCfPtFQ0DkJoY7JT/HDQPsmbWX/iZnNx38nf8uPVfmhcXDia+Uznb8jmvfOnBiSS3/SXqXo3HviXCZdEBSH7dOH904enyBHOfmqcdmqfNfbSTu/CNvKyN5fP1Nz7A1Z1nJZKvZZvthnOks3vPp2g85S0R6xqzXbvN3Tm49PybLSRoASwSjWCihdgIIGOwUFDXYKChrsFBQ02CkoaLBTUGQSGiIY91gee8N456MGvrgDafvkEx8fDhUmFt1bukIgQlfvqvMsgui+kE90y/xonSgNE17DQdfZ5868Xia9/YvcD/cMTxxkbr7IGeulLT1vvrVu7Ho8CVCz64PvyoqG2b0zk1ZetO+rZxn2QMcic7NgZGXuT1+Anz7wmFAlcffTYue31o3u5ohF1btG47KRF/IL1qdmJFPKhALTB08OCkZWMCWXICSxMqqDiLc/LSM1I/tT1xROtO38iDNfXIfrdv/HxMTOu3w6796A+RRaE92TEzsLQeZHq9Az4R046K4c8WXROw91zdBSRz4ZzY46GPfNE1hQw3BUUTVRhFO85eH6a9YVdEeJ1sNtRN+nZ74Ik18Vf9qZ3HPEgrufMhAkyL8JUH64aZt8vTFFpmL0msP5uyPw13ALbyQu4oAJib+U1Uzlnp/sDvuWxhwgnki2jUl8cZ7EDUwZT5eOttYA01rCtxF53CKnmz+y95M9viu3BqjYF2XgZGlJZWuryERX+ODCX2vrMzyR2hodn4J5gQgtcq+ZaCQcrSK7bCyLBCyai7rH+E2BH22GYKvAQZdkGXvHgiNereeIL4feMiLiCPkrA0biaRPPSD4jo2xppCtsJOWLVKqb4aJaNEgk6LniYl8B8DJ5b1eWRSorSxTfzcEZngRZDhH+25OJJLxPCsvy5pDI3U8PFwUuBQea/m2ARUM/noyWVGrjqCoaKd8YUZjuHDT0keNcgAf4b4sDCxCVuBrxFpZNtl30LdhzoJ64DsiFRxlpgjvzx/iBJQFPCWdsRXf+yzsq+CM7K+RA8GF+DxXJY42PwtXXtolD9Oh7ULHj5YKGSrXBlwqutSPQB/fD7Xzdlu51+bs3Q9HY+EwjP3othpq/ZJV/aXT/GW43NxBtneCPRpGlw5F5WDjCK9zx2rruLTCNJgaa+LTknnVNDvf9pa13gYwpiPwtwPDm3fmTO7bwhYrP9vY13zABBlI+exxXQxc+nlCLqklQFf96YrrxKf4Sta5pVuorKN/9coHQRcmJ5vrkJcV3d/KxmCR64+EycnjMnRw+JUknx+EDEseau6Cr+eiAWhQgMaXvx+sb2xa1cTQ/1bxjYbppVtmBGHkYvgG3RUo5yJnM4eZOyWOMD7cOaIJ9qgMa7y87qb809b4FcJ6MCHcLRDWFxx0XTrg3jHuc7oNDxHlF4+LZGFL54HKDXrDjJzB/rO5lQOFhj24qLxRonf2DCoddl/RodBv40SKwyjknsu42U0SZJpEjLvG6R3MsOOL+6w00npyLDbYnTjYGEipPW/HZ6WIr5Xlk3GzRjJmtrVd1Tqr8foH7LfYVXA31fcIY209OjZGE4jsWQrX84QWm1+2sgVBBw1a0JSIMQ80q0y3NPOYlYuSjGiP3Hp8y9ONOqD+tjaPTCeFPPmQGal8iH1+P/TD/2k3Abg5tzftl2D8jNcGeGOrugJ0f1da28LxtSMbmJ+c7+DNW4XGLmrcPden3YFlyhV6E7QnJvyofXG0QsLHkN8QFw6BwryuvWiiUKdvNFs21ui2JjhrOeeVV33zezHXXccST1hxx//Ueg6O7gmyw5XqypfK0tT6zUN53hOVCR06p04Pfty9cUvn9Avdb7Csik/g4KXVRQvXdI51FOBaAi79K9JKhZGjiNm6Ez4lBw+VME8OxH3Aodotq5IPtgg+0/ZjkrTPEkeaQB2+ZuStGJI0n+sg1aGj8VPz0F2c+zdf4wmbVLj2yQ0NvS90UA2Ecaed52zy/9IqWPOlaqONxs+eGuklHtcv9LpC/c4Fj1Iu+UHREbnDS3uTtHXOxBCjc61l4z/nqKunmYeJHg2yNaOss3GEhS8cRF5jXnq6UaeplyNwoT5jN5Wl42lqfWelEzZEmpBk2zuQ3Rgxc8ZjYVznWDHxIDE9eTObI2QJAbTDRNLAgXjau9CXYE8Hmp1qCGiMb8nd+zdCPHaKRdvcDsF8YH0ky8qAB0I3Y5sSTotvqfA32ktYq9hAEBb54ACZLhUty7Wby8QpcI+Z1Bh53SWuA/RXZ406o3iwUbNlGrIpDd1C9/gp88FyoERvsqbVNY+Dhlu+IY5vAvb4TrtzmZPgBSTeY+dHydVuwlR+37oQ6K1l6jngOFHZ7cFi6et8l41sv2b+ZOEXlaROfRdU25rE2D3bzJ1arMnEdej9i9FxxTuwrPQNfTCeEhY5ITVVLCErvqRa7ID4OHZNC74fyRO5+2hghecyIzsij32f0/UiOcwtY3Q8g7lQaZk60IGJrdQhC5PsnENSKsR+q5bhAuux7TbBfOj4TfqDzdwJffDz2eV7J/LHp7/H91w4d/Bho5HG/2dlavKdzAhpj0+IQlzvb8VsYP/pIhB/shRRU5IOPd1x6RVQ3fXzUzpT7xTm4xMNujF015mT4fkH3/4AFP1qEZCvPQW+MfWjMcq6p54gXvOrBYenqLSa+DMEAORt6NDxt4rMc2Wca3ryC3nZo7xVOAxlPt4RDOq641FenTzw006Wn2vOzcCjImZy54wwUPD314cMkbe7KTQDazAcUDLzwqsDdTxvxGLTHZX1iGt8S1vfjW0cfygHL+wFiQiqbm//Q22fgjdyp4vp+MgvPGYCGAtHI5xfKi0+kyb73wmfnoLLpnUHPIsP5p3q/etxqlajVn1v/L0MQnxXedMx1+a/m0ljqsie3jmb0WJakb0lHthzBHknm5KfwJJuuGxeAyR+w6lKYoHGdos/0a/TuTcxY/+uGjB7LkvSVhQazI9gpKCgoKNLBvgzrC9KRnWLFkOHgoxRfijUDGuwUNNgpKC43BKkLKJYHMkeTycpgx9KcARvmDZrv4iYWpxb6D58gS1OUOonXmeMiEbtOiLwfT/p6TbqUAosOsDNA2VLEYOXTJFdjhHUthst9sSJonBxjl/6TmpA//YdfsS5Jw8YCV3PcJHqKYG/Hk75eky61ACMPsa7f0liCDKZZHZRNLcKwloLdauRB2gFk+f2hqMPmQnPE4FQkemwI7leA9PUio56VGVTT1ur0mpMX3Nu0tmVDsGsHGrXL0Ir0gu3lNTVzvGdbbtfz5dILXk9L9WzDKzwct6XVJsOxrg92Nb00DDkm/2Pj5dRHGJQpJ1wa0wBkPRmxVp2+Qi96pTNKPbGELRK75H8/smfsWqDz9mWfwjjl7NjBT2KPyB9Zf6kFIXhRBhV60YvkhB4jbYHL2Ya1e1ieRUILU9c491WGejJbc3bdHBGMzkfLmWfilVsTwNmwHOGYmSgjETZu6Vsgr2fwMuanTNYFe47bdRCnUpONAefdWn9VO+rFlqsqXq8YSL5gqFtLy2HUNdQ1AbucXc1UpO9Id9WT8kvNh28hohWHkQfxLi08m4mVFMDb8aSjV1+pPUxxG6U0LJh0mOSqBbraVA95lYPy2S8ruP1AgLIqi8v0agzlxlxm0b4iu67uCSrF6gRKo/ryv8bTkZ1izYAGOwUNdgoKmrNTUKQHiejOrGiwY6/TFKtfqX0jussEbTBRsw3qPTHewZ3Pbian26zBGRv6wGdXVCn3Enjh8Niz1TV8doP79DIxMptB+exeI1RxYbpEd6xaopVpauGN8Q7ufHazGuytoQ98dlWVdMCe+OxObHVkWFoxKdIdoa52DfLZkXTwSGRpIHmswdpbWoQf36RyW6L70s4ahM3DK7JooTb0ttyG0yLFL+EYvfDZdTJ9/E3HzFK1PkqUog9SGrDc5okYnvPSccudsysnvBjqenI7f0sL0jbx1S6LVMJweV0qC80m6UBew9+eprskvSaZuhuJfAg3ZG+88Qj9DivkKWdHK8tntzLa5Z4aR6K7L1mgF3q5y8/gHvjsS6GHuFnmhc9uNiMVPrut1Ug/pXGzcU2vxmB352LbrlLp0b7cBZEZPrs+D/bHMi98diuZbnx2K6v1LZCxS2yHBpQdvOaVDHan6y5G9k38I7qn1AW+c3NXIAA0WQxO58xHHvbAK0vdXzGie46d07HlUoTz+I+tl0syFidOVynP1thxxJc4S8NLmcL5N0PEjke4VojsViO7vDprkQoirCVni89dQDZZjn9Ed3c+u0rKdslrvbHPPTyDwExBX4JefalWqwc+ux1b3d1IjFJy7uUGj3x2TGnvqwKUz55SGkOxuqN9RXZd1RPUZVgSocgEKJ+djuwUFDTYKWiwU1Cs3ZydgkKD7Hv0esrB7vxzuZbNrbKvwUAq92Vt3chnByPF14KN7SbSlqyvPyKwkmdivHt6PrujXhPZ3fX57O4kdvUHQZOdJg8atYLXp9VcNiO7mfisd5BCxlDZ19o7KXx5WLuRz25564aeUI69iNRKtBCnrcZOh25ZkLJeE9nd9fnsHkjsJvttSdDIyoy1+nx25fmZijdMjA3sibe6hHHdwGfHro+PToGR7mitC+Md2RekrtfzQ+OX5Dp9gQW53eRBp4HHYaaHlyUGMhPsiB9VsOWYhcBjrKd5MTTz2R1fMwPIyxs1sJfIsmVioSX2pBe9Vge31DPAZL+tB3XZp0Pyidxy9lWW9wTt3SaGvumiak0GU1kzfv/qbDzxtDRjf5R5lmF2xdK1W5PdHfnsS3sMqsXYrcs+pQdlrwVCSGp8dgM9Wu4aTc7ju8uQffLqTVmqvYhTeZK7yz2obvta5zfGc9jwyHULirrj3eJmUaZhbY0sIgUdVxHAJdlcvod7+3lDpstc0rgIZcv2xshXvV5Tb+uXodiPCE5s9bVN+8gxDNzae7mQQAJF7jnMciJtHW78dGNg2LZ3zudS05s65R8vWa/7w9pT9jEj4XIY2e1fO6InQGu+LcvD2i0p154J5V6DyMMTYzQNHZ6KnsoZmPLz2d1J7Hanpomqn6qoywb0+eyrH9inuQvls1OsgmjPIimrbzWGYjUB+dOK8tkpKGiwU1DQYKegoMFOQUGDnYKCBjsFBQ12Cgoa7BQUNNgpKGiwU9Bgp6CgwU5BQYOdgoIGOwUFDXYKChrsFKsbNZU/LSm8MhLayHBZZRe9LY/CR5y8eR4nz4nb0VGAvxrnIhcTdq3pbXkUqxNcoLI0csVf+oekWAcS6/Du+Yn+6cJ7QlVZMcTnqvfltdbx6JG+VTOzaoVQWBWMM6VMKDB98OSg0LKCKbkEoQWpfRCxBzoWSdsSUpodWH+dYHjp9T2Gg1tZvXw5c+8f2KLjj3KP5bGBwCI/Jj57/TDxn+DT+960EMrcrJFUxosoQWxhYlHsuR6zbHGvvXV8yzy2sGxSkoPWhYpGD/JbYjvJxNalu+fkoQLE/uP8xKVpy+rZGDf+YF0ANhx9VF+Rqf6wCPaenjpoU9TvqlI264Df5Ib+NL3+6ieebfr7+UPltzzS0wN5RbNxpiAupmlTzNl/LhydJW2L8fjBbAj1yZ/t5A1nIo3ko6enZ7b8+GwW6BXL1wfGXjz1tflHdo2gpgk+Rp7Y9U8vwsS04NN3rOxM1nW+3SP2SQ3iNUQan3ixYWRW6CApH2BKrlVlCyUbKkhB6fzAtz7aF5fOxJZRZsc/zPBbYjtiIrehc6ZH7OZUx/Nf5OflfTvnnBjnUUmHxefINDf+g5L8cDG3uGLBbpHG3BeJlEOYjBfARCPhaJVUvLU3Fzho6IObYQEe4EsWBxYgyoq18RaWTbZd5DdfbtqWFeP650Sv3hSQumVn+0Q26BXL56C3HkLEl6d6yTZBCOr7yJbgU8t51Ab10f8fFAJ5ERoGYV7X5ibQyBbGXOGRAcPjxfMgmUNq+/pgl64ddykWWsJ4XlUefV+gb2BuGEajfESD6+fFxMCp6eKS8sqTWbIaU9Gd//KOCtI/bVA0Nj7TKI8yCeglDiO512H4BtwWKeUgZzKHmzsl1ypn6fuz5KEMt5wVPjqly/dWHEpkg16xPAksC/uJL8lHki/YL25pfarHAszeUybG+/EhYRiHQJfB1Z1nNLJ5XJ0vVpTsrT0rXyH42sO6dlua2YGUDpHZGDpQdEXfwNAfpNw8lb/hcwP9VxQdWF/JrXywY+grknw4uqn8blhUgp0l/q19iWx+PfbD/Gs3Abs5tDXvl+FKvrYZWGWBBxayIti/IFo0LIYax8X6s0KvWN7M//MktIhBR9ArhR/v022iTw2ITTfu/LKwdVHQMNix9/6YfmQfZjWy+Xwn/4xYMdTdWy21aVZay+24Ham6phIK+9Jz0uK78HDhygc7cfh2KVwrr/rm82J/CDFM/HvLzF0x/rKY6CMX0KHxU/HTX5z5tNAToJyn0lCVZaht4tgs0hsTXd0ue1beEnw6K/pUj4vjiVvgR5qCp5oefKc5Yi+bnxqOyX1ySnmmeszULpREKbpm4Ozwc1Mcu+n2ViE7Se2vtCK8lZv+1fAdiZUPdn4wgj3iNBru+LPmJOCA/cL4SJKRvwN0I7Y58aR4Ta1TdlfSw2zCKPwim/TmAHeS/LObd7bgrlx+S0h7FJ+qaG1tNXfXAT5nnzM1EWRzYsude1v5uZcOAb52t7ZdGVG+BBQnh597LcnmV5VFhQwlKmUqDp+B28NbSy6Nxc8WZ0nOzsK2buggIw0Hd0KdOtfM4xe2wsyJFgTRSHVImNl8AkGtGPuhWo4LtJbxm4VZ+ZixEHwym/QysO0meJgMrt3biGdJoJKCWuHqiBWfqmhra4No+H+3AQJtTJOcndE2UXpq2zb4N76lUNgGByLVtaRfxV2J+G54hf8itSOX8aXnJGxy+OIU3laz8StCxIOUl5s/WyvyWe7ic/GzgysXA+Zg7z8xs/fEOfhJexU0xj40pumeWvhNbv5Db5+BN3KniutJmledMwANBcJEfuD5hfLiE8Kywzz8exYGexJC2aR3tH5mprMRTnfunTksRMPrnTPT9fM6n+qxjtk1e+K0pmDqeHj3casFphFedoOmYH/u1HT9OSlvGTk8vbdzXNtuHtJM8BJnzo98d4StuX1D1Kq6tGLTlrrXxoaTxezKxoB3ugBXwZ7z1LB8bogFigyiFTz97l5zacwHKc7LNJVz8597fFQe5aONXcG8/7OdEWSaLpACN6brxlFP7UrZMzT+MoowBMY9NCsLOaUQxTlJv36HYKJ/94P5a7uCTG6P47CXxcFOQeHzFYkSwSgoaLBTUNBgp6CgwU5BQSeoFOnCj/eRubbw+aVndGSnWDMIms4SjJZ01kg7GN9DzkMvBoP5XVWSZqVG81JQ3Y5ILRNfBG0WrUrgX1pqVC++u9u0l/KqY4QBrF4hr77aWzLC8C53Z2uwuAtagbcvUtgEe9pA5u/m3rV4VTw27C+/BR0bTwisfae5WRAyytIW2J3CGrn8B3JsIm2JH7q3fztYg5WBgMZ6Fga7OHAJHSSFrLLJj1BSIIoV6kgnfMNKe9PIKEcKmGIJW15IdOXCv0g3Rlq9CFoTtqbYFvcz6kHpndWKNAdrVmNKnh0t/FCCnINdHbgwMoxm0glgqFCGPiQFqL7jdYMy1o7aSDegG1/cbo5GpEmWzIL0WoyJkHS+YnW4R06hid1PBV6W/WGppylefbGfielnxieoQW9niT4IsZNTkPlq7RbCxqwHYSdvI1dBdhmUajmy9Rg2noIevYxcgoS/BGLL4Z9iRdIYZZqI3eMfp3IxwakNJjjtqRxagT1dzgpkMYOnyIKcHbn3fSqJL7adlKIlRo6NIIw8XuWsc58UDPQiGCNtgqPNZyiyazXGYQXSOgVVvlmuOWDjEJ/qbA7ZDfcohVjEVjthlPoQb2sr8phQrXqgTLTwQ4lbsCNlSVuTPUubYu5pSKs137DFGKvu4zS2IWXNRi9cEuWcyBsi0UqCjXqsTGZtVwZNlmF1od17IIu7XyZxr/wygpyTV+Sc3CLX7BelZ4MOS6ILYJROtc/afJSQqia8Zn8mwsrvEQ7H7yFMMFp6f3iyQYeU6QKYIKOxnslLM87wWbi6x/Xldk86Z0JqOXuG0qiMrI+g5VGFluNoL5OEPcUEYwkCliA6CBQUy3ZKpL2A7OvVkwY7hX+jra4R8uFk8Rc02Cn8j8Asze0on51i+a4BKyzAiAAyyrZmR6W2QGz6WRyblpi1lC2wY7iDnkAuV3knnQNl1S5TJHtbZ0dpZUQuDVJeZw96mw6kGTJOnBArArl6Uuspl3KJJ9K52IxG+zJmMyitZCbdH1CRNynOaQzGWPnAEjEMy8VYCkSpFgw10r56WaRGWynLxbanEkY+JIE0yilcJ6gWd+MYqO2g/+HKTHo3yEI61rvwv5YKbs5nkNcQdmRryfwGGvQUHlZjkEuZnruOPI/AlnRy5DhP0aX83kjn9J5PCo9pDDJmJA6jrdrSMo2xq/SQbiCZnIB0t4wQpHhGUSwfOM+FHup8M8BxNUaOO8OdbEizoU40lW+mIs2detpJpb6dFYXYlmNu2k+zr7qPZYqF6ei+FAhvLfD+1NF9z1kURh2e+ayrS1GZqzz756UGU18+0Q+8puDEjiM3Rjah7ExMtyXf0gnqsiC12LPMABodZOjr0n+Wb6M3ETmWmYOwvCfRG7G+2OKbZhsZKJG6nVTBSF3WwQKPEtvOMPXGODATpSamfWjMLxnVJZFIFexjgNkHXJR/G6gwDPPvaaooga5wuKRaHJrJf5URYMqK1zMANdEw2UssLIkEqvaFu0CuI/sVdwl1JnSVhksqoYSBk1Fg1of5t2DKyojsQLh4X5fQrmZfJCDIK9PJa60gNpYKNnoMdjk9RuoHUiaC0nc1bVYXT9QahKR5KtI2Q1oJIMuV97XKwA1aQdfE5tYixQqrfShSx/Rr4xO3Qmw9rO+Ap9hxtlqtyh2C3esmXpsWR2YysB46B9HByYtRgL8pmCiYEQsXh14vWXj68FPA1+UJ76AZmtot1hlx428mQnFAb8CNeRBkJl7S5BxEdviVyedvEL7Ev1z0JSLvJaO83KehGo2zT6U4Qc1uUNJ5JpJ24WVjYw2Q7IWX5yDBwKE+6N2pNuhlgcHPfEB9b812FnAIkqRzvjMIZ6SXrY6yDY39bEMvwGdCcIbvuH422WKtbLQBzjbD+UMw3wZsHxRp+o3IDr4aiIvK5uoHvkumpPXQx+nkEYt2EhsPORxV7upjggWXsTWFgLq2Hv6F5Uw5G9rU8/1/4djzULcfDg5zUEfKyR/5Bgn2pUcufFtoLhbsqaurG+SkvYTCP4FQQTZLSd17nPytrses7OQL+WhTD/dZDn0P9uyHR0M6ZWOfRf+6QXg3+J790r8HQ1p5wpZq42UyslNkDMWLr04BsEwlCekYB1xAt86XuHj+5S3a5rG2trYJ/v2oI+tMovg65/c+fSSQd4lXVnE3QDtRltQpY0fO/WRK2GoXimJKC60SxUYa7BQp4m9HP8DnxUz9gyQ5CUHtd0g8VXGbpdoDXWzzorB1RAxJFIeNpQDzI3EsRp42+RTrJLRbTCOTTC9/FX6x4eck96yFbiLjSEBRFq1iP3OdsJW3jbkH+Fcmb2ON8ngbGRrsFEta0Sus4ONjOEaS7sZomGsEKJgpl1+H/Z83RIonxUguFzP0mjBXADBZeBu/V7BcK4rUxfOVb0y5WVnBjvLHyEdRO1E2j8O3zAP8tvg2OT7/e2e4uFPYGo/fdQdp8fHw3KhRHm/jbx2Oh76MgGLNgI7sFDTYKShosFNQ0GCnoKDBTkFBg52CggY7BQUNdgoKGuwUFDTYKShk/D+CzwTxe5gL+AAAAABJRU5ErkJggg==</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2010-08-02 16:11:41 +0100" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-004.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Language development, outcome: 4.1 Comprehensive language development (measured with the Reynell test) at 6 to 9 months follow up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2010-08-02 16:11:45 +0100" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-004.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Language development, outcome: 4.2 Expressive language development (measured with Reynell, Schlichting) at 6 to 9 months follow up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-08-24 20:44:46 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-08-24 20:44:46 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-12-06 19:20:23 +0000" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-08-24 20:44:46 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="4">
<TR>
<TH>
<P>CENTRAL</P>
</TH>
<TH>
<P>PubMed</P>
</TH>
<TH>
<P>EMBASE (Ovid)</P>
</TH>
<TH>
<P>CINAHL (EBSCO)</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#1 MeSH descriptor Otitis Media with Effusion explode all trees<BR/>#2 MeSH descriptor Ear, Middle explode all trees with qualifier: SE<BR/>#3 (glue NEXT ear) OR (otitis NEXT media) OR (middle NEXT ear NEAR effusion*) OR (otitis NEAR effusion*) OR (nonsuppurative NEXT otitis) OR (non NEXT suppurative NEXT otitis)<BR/>#4 tympanitis OR (serous NEAR otitis) OR (secretory NEAR otitis)<BR/>#5 (mucoid* NEAR otitis) OR (mucous NEAR otitis) OR (seromuco* NEAR otitis) OR (sero NEXT muco* NEAR otitis OR otitis NEAR serosa)<BR/>#6 (mucoid* NEAR middle NEXT ear*) OR (mucous NEAR middle NEXT ear*) OR (seromuc* NEAR middle NEXT ear*)<BR/>#7 (adhesive NEAR otitis) OR (exudative NEAR otitis)<BR/>#8 (OME OR SOM) AND (otitis OR ear*)<BR/>#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)<BR/>#10 MeSH descriptor Middle Ear Ventilation explode all trees<BR/>#11 grommet* OR tubulation OR middle NEXT ear NEAR ventilat*<BR/>#12 (ventilat* OR tympanostomy OR middle NEXT ear OR tympanic) NEAR tube*<BR/>#13 ear* NEAR insert* NEAR tube*<BR/>#14 (#10 OR #11 OR #12 OR #13)<BR/>#15 (#9 AND #14)</P>
</TD>
<TD VALIGN="TOP">
<P>#1 "Otitis Media with Effusion"[Mesh]<BR/>#2 "Ear, Middle/secretion"[Mesh]<BR/>#3 (glue [tiab] AND ear [tiab]) OR (otitis [tiab]) AND media [tiab]) OR (middle [tiab] AND ear [tiab] AND effusion* [tiab]) OR (otitis [tiab] AND effusion* [tiab]) OR (nonsuppurative [tiab] AND otitis [tiab]) OR (non [tiab] AND suppurative [tiab] AND otitis [tiab])<BR/>#4 tympanitis [tiab] OR (serous [tiab] AND otitis [tiab]) OR (secretory [tiab] AND otitis [tiab])<BR/>#5 (mucoid* [tiab] AND otitis [tiab]) OR (mucous [tiab] AND otitis [tiab]) OR (seromuco* [tiab] AND otitis [tiab]) OR (sero [tiab] AND muco* [tiab] AND otitis [tiab]) OR (otitis [tiab] AND serosa [tiab])<BR/>#6 (mucoid* [tiab] AND middle [tiab] AND ear* [tiab]) OR (mucous [tiab] AND middle [tiab] AND ear* [tiab]) OR (seromuc* [tiab] AND middle [tiab] AND ear* [tiab])<BR/>#7 (adhesive [tiab] AND otitis [tiab]) OR (exudative [tiab] AND otitis [tiab])<BR/>#8 (OME [tiab] OR SOM [tiab]) AND (otitis [tiab] OR ear* [tiab])<BR/>#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8<BR/>#10 "Middle Ear Ventilation"[Mesh]<BR/>#11 grommet* [tiab] OR tubulation [tiab] OR (middle AND ear [tiab] AND ventilat* [tiab])<BR/>#12 (ventilat* [tiab] OR tympanostomy [tiab] OR (middle [tiab] AND (ear [tiab] OR tympanic [tiab])) AND tube* [tiab])<BR/>#13 ear* [tiab] AND insert* [tiab] AND tube* [tiab]<BR/>#14 #10 OR #11 OR #12 OR #13<BR/>#15 #9 AND #14<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 exp chronic otitis media/ or exp secretory otitis media/<BR/>2 Middle Ear Effusion/<BR/>3 Effusion/ and Middle Ear/<BR/>4 ((glue and ear) or (otitis and media) or (middle and ear and effusion*) or (otitis and effusion*) or (nonsuppurative and otitis) or (non and suppurative and otitis)).tw.<BR/>5 (tympanitis or (serous and otitis) or (secretory and otitis)).tw.<BR/>6 ((mucoid* and otitis) or (mucous and otitis) or (seromuco* and otitis) or (sero and muco* and otitis) or (otitis and serosa)).tw.<BR/>7 ((mucoid* and middle and ear*) or (mucous and middle and ear*) or (seromuc* and middle and ear*)).tw.<BR/>8 ((adhesive and otitis) or (exudative and otitis)).tw.<BR/>9 ((OME or SOM) and (otitis or ear*)).tw.<BR/>10 6 or 3 or 7 or 9 or 2 or 8 or 1 or 4 or 5<BR/>11 MIDDLE EAR VENTILATION/<BR/>12 TYMPANOSTOMY TUBE/<BR/>13 (grommet* or tubulation or (middle and ear and ventilat*)).tw.<BR/>14 ((ventilat* or tympanostomy or (middle and (ear or tympanic))) and tube*).tw.<BR/>15 (ear* and insert* and tube*).tw.<BR/>16 11 or 13 or 12 or 15 or 14<BR/>17 16 and 10</P>
</TD>
<TD VALIGN="TOP">
<P>S1 (MH "Otitis Media with Effusion")<BR/>S2 TX ( glue AND ear ) or TX ( otitis AND media ) or TX ( middle AND ear AND effusion* )<BR/>S3 TX ( nonsuppurative AND otitis ) or TX ( non AND suppurative AND otitis )<BR/>S4 TX tympanitis or TX ( serous AND otitis ) or TX ( secretory AND otitis )<BR/>S5 TX ( mucoid* AND otitis ) or TX ( mucous AND otitis ) or TX ( seromuco* AND otitis )<BR/>S6 TX ( sero AND muco* AND otitis ) or TX ( otitis AND serosa )<BR/>S7 TX ( mucoid* AND middle AND ear* ) or TX ( mucous AND middle AND ear* ) or TX ( seromuc* AND middle AND ear* )<BR/>S8 TX ( adhesive AND otitis ) or TX ( exudative AND otitis )<BR/>S9 S1 or S2 or S3 or S4 or S5 or S7 or S8<BR/>S10 TX ( OME OR SOM ) and TX ( otitis OR ear* )<BR/>S11 s9 OR s10<BR/>S12 (MH "Middle Ear Ventilation")<BR/>S13 TX grommet* or TX tubulation or TX ( middle AND ear AND ventilat* )<BR/>S14 TX ( ventilat* or tympanostomy ) or TX ( middle and tube ) and TX ( ear OR tympanic )<BR/>S15 TX ear* and insert* and tube*<BR/>S16 s12 or S13 or S14 or S15<BR/>S17 S11 and S16<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TH>
<P>Web of Science</P>
</TH>
<TH>
<P>BIOSIS Previews (Ovid)</P>
</TH>
<TH>
<P>CAB Abstracts (Ovid)</P>
</TH>
<TH>
<P>ISCTRN (mRCT)</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#1 TS=((glue and ear) or (otitis and media) or (middle and ear and effusion*) or (otitis and effusion*) or (nonsuppurative and otitis) or (non and suppurative and otitis))<BR/>#2 TS=(tympanitis or (serous and otitis) or (secretory and otitis))<BR/>#3 TS=((mucoid* and otitis) or (mucous and otitis) or (seromuco* and otitis) or (sero and muco* and otitis) or (otitis and serosa))<BR/>#4 TS=((mucoid* and middle and ear*) or (mucous and middle and ear*) or (seromuc* and middle and ear*))<BR/>#5 TS=((adhesive and otitis) or (exudative and otitis))<BR/>#6 TS=((OME or SOM) and (otitis or ear*))<BR/>#7 TS=(grommet* or tubulation or (middle and ear and ventilat*))<BR/>#8 TS=((ventilat* or tympanostomy or (middle and (ear or tympanic))) and tube*)<BR/>#9 TS=(ear* and insert* and tube*)<BR/>#10 #6 OR #5 OR #4 OR #3 OR #2 OR #1<BR/>#11 #9 OR #8 OR #7<BR/>#12 #11 AND #10<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 ((glue and ear) or (otitis and media) or (middle and ear and effusion*) or (otitis and effusion*) or (nonsuppurative and otitis) or (non and suppurative and otitis)).tw.<BR/>2 (tympanitis or (serous and otitis) or (secretory and otitis)).tw.<BR/>3 ((mucoid* and otitis) or (mucous and otitis) or (seromuco* and otitis) or (sero and muco* and otitis) or (otitis and serosa)).tw.<BR/>4 ((mucoid* and middle and ear*) or (mucous and middle and ear*) or (seromuc* and middle and ear*)).tw.<BR/>5 ((adhesive and otitis) or (exudative and otitis)).tw.<BR/>6 ((OME or SOM) and (otitis or ear*)).tw.<BR/>7 1 OR 2 OR 3 OR 4 OR 5 OR 6<BR/>8 (grommet* or tubulation or (middle and ear and ventilat*)).tw.<BR/>9 ((ventilat* or tympanostomy or (middle and (ear or tympanic))) and tube*).tw.<BR/>10 (ear* and insert* and tube*).tw.<BR/>11 8 OR 9 OR 10<BR/>12 7 AND 11</P>
</TD>
<TD VALIGN="TOP">
<P>1 ((glue and ear) or (otitis and media) or (middle and ear and effusion*) or (otitis and effusion*) or (nonsuppurative and otitis) or (non and suppurative and otitis)).tw.<BR/>2 (tympanitis or (serous and otitis) or (secretory and otitis)).tw.<BR/>3 ((mucoid* and otitis) or (mucous and otitis) or (seromuco* and otitis) or (sero and muco* and otitis) or (otitis and serosa)).tw.<BR/>4 ((mucoid* and middle and ear*) or (mucous and middle and ear*) or (seromuc* and middle and ear*)).tw.<BR/>5 ((adhesive and otitis) or (exudative and otitis)).tw.<BR/>6 ((OME or SOM) and (otitis or ear*)).tw.<BR/>7 1 or 2 or 3 or 4 or 5 or 6<BR/>8 (grommet* or tubulation or (middle and ear and ventilat*)).tw.<BR/>9 ((ventilat* or tympanostomy or (middle and (ear or tympanic))) and tube*).tw.<BR/>10 (ear* and insert* and tube*).tw.<BR/>11 8 OR 9 OR 10<BR/>12 7 AND 11</P>
</TD>
<TD VALIGN="TOP">
<P>((otitis OR effusion% OR glue ear OR tympanitis OR OME) AND (grommet% OR ventilat% OR tympanostomy OR tubulation OR tube%))<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>